Consensus Recommendations for the Postmortem Diag

Neurobiology of Aging 18, S1-S2

DOI: 10.1016/s0197-4580(97)00057-2

Citation Report

#	Article	IF	CITATIONS
2	Comparison of Neuropathologic Criteria for the Diagnosis of Alzheimer's Disease. Neurobiology of Aging, 1997, 18, S99-S105.	1.5	88
3	Strategies for Improving the Postmortem Neuropathological Diagnosis of Alzheimer's Disease. Neurobiology of Aging, 1997, 18, S75-S79.	1.5	34
4	Progression of neurofibrillary changes and PHF-Ï,, in end-stage Alzheimer's disease is different from plaque and cortical microglial pathology. Neurobiology of Aging, 1998, 19, 517-525.	1.5	67
5	Clinicopathologic Studies in Cognitively Healthy Aging and Alzheimer Disease. Archives of Neurology, 1998, 55, 326.	4.9	630
6	Brain volume preserved in healthy elderly through the eleventh decade. Neurology, 1998, 51, 1555-1562.	1.5	138
7	Neurofibrillary Tangles and Alzheimer's Disease. European Neurology, 1998, 40, 130-140.	0.6	138
8	Electrochemical Analysis of Protein Nitrotyrosine and Dityrosine in the Alzheimer Brain Indicates Region-Specific Accumulation. Journal of Neuroscience, 1998, 18, 8126-8132.	1.7	478
9	Neurofibrillary Tangles in Nondemented Elderly Subjects and Mild Alzheimer Disease. Archives of Neurology, 1999, 56, 713.	4.9	194
10	Specific temporoparietal gyral atrophy reflects the pattern of language dissolution in Alzheimer's disease. Brain, 1999, 122, 675-686.	3.7	87
11	Biomarkers of Alzheimer Disease. Archives of Neurology, 1999, 56, 281.	4.9	91
11	Biomarkers of Alzheimer Disease. Archives of Neurology, 1999, 56, 281.  Increased DNA Oxidation and Decreased Levels of Repair Products in Alzheimer's Disease Ventricular CSF. Journal of Neurochemistry, 1999, 72, 771-776.	4.9	91 254
	Increased DNA Oxidation and Decreased Levels of Repair Products in Alzheimer's Disease Ventricular		
12	Increased DNA Oxidation and Decreased Levels of Repair Products in Alzheimer's Disease Ventricular CSF. Journal of Neurochemistry, 1999, 72, 771-776.  High-throughput quantitative histological analysis of Alzheimer's disease pathology using a confocal	2.1	254
12	Increased DNA Oxidation and Decreased Levels of Repair Products in Alzheimer's Disease Ventricular CSF. Journal of Neurochemistry, 1999, 72, 771-776.  High-throughput quantitative histological analysis of Alzheimer's disease pathology using a confocal digital microscanner. Nature Biotechnology, 1999, 17, 53-57.  Antibodies to ?-synuclein detect Lewy bodies in many Down's syndrome brains with Alzheimer's disease.	2.1 9.4	<b>254</b> 38
12 13	Increased DNA Oxidation and Decreased Levels of Repair Products in Alzheimer's Disease Ventricular CSF. Journal of Neurochemistry, 1999, 72, 771-776.  High-throughput quantitative histological analysis of Alzheimer's disease pathology using a confocal digital microscanner. Nature Biotechnology, 1999, 17, 53-57.  Antibodies to ?-synuclein detect Lewy bodies in many Down's syndrome brains with Alzheimer's disease. Annals of Neurology, 1999, 45, 353-357.  Reanalysis of the first case of Alzheimer's disease. European Archives of Psychiatry and Clinical	2.1 9.4 2.8	254 38 289
12 13 14	Increased DNA Oxidation and Decreased Levels of Repair Products in Alzheimer's Disease Ventricular CSF. Journal of Neurochemistry, 1999, 72, 771-776.  High-throughput quantitative histological analysis of Alzheimer's disease pathology using a confocal digital microscanner. Nature Biotechnology, 1999, 17, 53-57.  Antibodies to ?-synuclein detect Lewy bodies in many Down's syndrome brains with Alzheimer's disease. Annals of Neurology, 1999, 45, 353-357.  Reanalysis of the first case of Alzheimer's disease. European Archives of Psychiatry and Clinical Neuroscience, 1999, 249, S10-S13.  Missense and silent tau gene mutations cause frontotemporal dementia with parkinsonism-chromosome 17 type, by affecting multiple alternative RNA splicing regulatory elements.	2.1 9.4 2.8	254 38 289 41
12 13 14 15	Increased DNA Oxidation and Decreased Levels of Repair Products in Alzheimer's Disease Ventricular CSF. Journal of Neurochemistry, 1999, 72, 771-776.  High-throughput quantitative histological analysis of Alzheimer's disease pathology using a confocal digital microscanner. Nature Biotechnology, 1999, 17, 53-57.  Antibodies to ?-synuclein detect Lewy bodies in many Down's syndrome brains with Alzheimer's disease. Annals of Neurology, 1999, 45, 353-357.  Reanalysis of the first case of Alzheimer's disease. European Archives of Psychiatry and Clinical Neuroscience, 1999, 249, S10-S13.  Missense and silent tau gene mutations cause frontotemporal dementia with parkinsonism-chromosome 17 type, by affecting multiple alternative RNA splicing regulatory elements. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 5598-5603.	2.1 9.4 2.8 1.8	254 38 289 41 501

#	Article	IF	Citations
20	Apolipoprotein EÂε4 Is Associated with Neuronal Loss in the Substantia nigra in Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders, 1999, 10, 437-441.	0.7	8
21	Deposition of $\hat{l}^2$ -Amyloid Subtypes 40 and 42 Differentiates Dementia With Lewy Bodies From Alzheimer Disease. Archives of Neurology, 1999, 56, 1111.	4.9	45
22	Clinicoâ€Neuropathological Correlation of Alzheimer's Disease in a Communityâ€Based Case Series. Journal of the American Geriatrics Society, 1999, 47, 564-569.	1.3	354
23	The pathology of REM sleep behavior disorder with comorbid Lewy body dementia. Neurology, 2000, 55, 1730-1732.	1.5	104
24	Neuropathologic Substrates of Ischemic Vascular Dementia. Journal of Neuropathology and Experimental Neurology, 2000, 59, 931-945.	0.9	265
25	Immunohistochemical localization of the P2Y1 purinergic receptor in Alzheimer's disease. NeuroReport, 2000, 11, 3799-3803.	0.6	58
26	A Unifying Hypothesis of Alzheimer's Disease. IV. Causation and Sequence of Events. Reviews in the Neurosciences, 2000, 11, 213-328.	1.4	78
27	Tau pathology: a marker of neurodegenerative disorders. Current Opinion in Neurology, 2000, 13, 371-376.	1.8	113
28	Sequence of AÎ <sup>2</sup> -Protein Deposition in the Human Medial Temporal Lobe. Journal of Neuropathology and Experimental Neurology, 2000, 59, 733-748.	0.9	305
29	Predicting Conversion to Alzheimer Disease Using Standardized Clinical Information. Archives of Neurology, 2000, 57, 675.	4.9	328
30	Broadly altered expression of the mRNA isoforms of FE65, a facilitator of beta amyloidogenesis, in Alzheimer cerebellum and other brain regions. , 2000, 60, 73-86.		26
31	Decreased thioredoxin and increased thioredoxin reductase levels in alzheimer's disease brain. Free Radical Biology and Medicine, 2000, 28, 418-427.	1.3	188
32	Decreased base excision repair and increased helicase activity in Alzheimer's disease brain. Brain Research, 2000, 855, 116-123.	1.1	162
33	Serum Zinc Levels and Alzheimer's Disease. Biological Trace Element Research, 2000, 75, 79-85.	1.9	65
34	Usefulness of MRI measures of entorhinal cortex versus hippocampus in AD. Neurology, 2000, 54, 1760-1767.	1.5	356
35	AMY plaques in familial AD. Neurology, 2000, 54, 100-100.	1.5	13
36	Hippocampal and cortical atrophy predict dementia in subcortical ischemic vascular disease. Neurology, 2000, 55, 1626-1635.	1.5	396
37	Cortical Inflammation in Alzheimer Disease but Not Dementia With Lewy Bodies. Archives of Neurology, 2000, 57, 817.	4.9	67

#	Article	IF	Citations
38	Effect of Anti-inflammatory Medications on Neuropathological Findings in Alzheimer Disease. Archives of Neurology, 2000, 57, 831.	4.9	69
39	Research evaluation and diagnosis of probable Alzheimer's disease over the last two decades: I. Neurology, 2000, 55, 1854-1862.	1.5	150
40	"Preclinical―AD revisited. Neurology, 2000, 55, 370-376.	1.5	347
41	Novel Method to Quantify Neuropil Threads in Brains from Elders With or Without Cognitive Impairment. Journal of Histochemistry and Cytochemistry, 2000, 48, 1627-1637.	1.3	77
42	Research evaluation and diagnosis of possible Alzheimer's disease over the last two decades: II. Neurology, 2000, 55, 1863-1869.	1.5	112
43	Expression of tau immunoreactivity in the spinal motor neurons of Alzheimer's disease. Neurology, 2000, 55, 1727-1730.	1.5	28
44	Glucose Hypometabolism and Neuropathological Correlates in Brains of Dementia with Lewy Bodies. Experimental Neurology, 2000, 162, 247-256.	2.0	185
45	Specific downregulation of presenilin 2 gene expression is prominent during early stages of sporadic late-onset Alzheimer's disease. Molecular Brain Research, 2000, 78, 138-145.	2.5	19
46	MRI description of cerebral atrophy in mouse lemur primates. Neurobiology of Aging, 2000, 21, 81-88.	1.5	48
47	Autopsy in dementing disorders of the elderly. Current Diagnostic Pathology, 2000, 6, 181-191.	0.4	2
48	î²-Amyloid1–42 Binds to î±7 Nicotinic Acetylcholine Receptor with High Affinity. Journal of Biological Chemistry, 2000, 275, 5626-5632.	1.6	720
49	Suicide and Alzheimer's pathology in the elderly: a case–control study. Biological Psychiatry, 2001, 49, 137-145.	0.7	104
50	Clinical and Pathological Diagnosis of Frontotemporal Dementia. Archives of Neurology, 2001, 58, 1803.	4.9	1,381
51	Current Concepts in Mild Cognitive Impairment. Archives of Neurology, 2001, 58, 1985.	4.9	4,117
52	Up-Regulation of Calcineurin $\hat{Al^2}$ mRNA in the Alzheimer's Disease Brain: Assessment by cDNA Microarray. Biochemical and Biophysical Research Communications, 2001, 284, 310-316.	1.0	112
53	Acrolein is increased in Alzheimer's disease brain and is toxic to primary hippocampal cultures. Neurobiology of Aging, 2001, 22, 187-194.	1.5	410
54	Protein oxidation in the brain in Alzheimer's disease. Neuroscience, 2001, 103, 373-383.	1.1	474
55	Reduced neprilysin in high plaque areas of Alzheimer brain: a possible relationship to deficient degradation of $\hat{l}^2$ -amyloid peptide. Neuroscience Letters, 2001, 297, 97-100.	1.0	332

#	ARTICLE	IF	CITATIONS
56	Hyperphosphorylation of the retinoblastoma gene product and altered subcellular distribution of E2F-1 during Alzheimer's disease and amyotrophic lateral sclerosis. Journal of Alzheimer's Disease, 2001, 3, 377-385.	1.2	65
57	Brain Aging in Strepsirhine Primates. , 2001, , 421-433.		7
58	Binding Characteristics of Radiofluorinated 6-Dialkylamino-2-Naphthylethylidene Derivatives as Positron Emission Tomography Imaging Probes for β-Amyloid Plaques in Alzheimer's Disease. Journal of Neuroscience, 2001, 21, RC189-RC189.	1.7	390
59	Olfactory centres in Alzheimer's disease: olfactory bulb is involved in early Braak's stages. NeuroReport, 2001, 12, 285-288.	0.6	212
60	Preclinical prediction of AD using neuropsychological tests. Journal of the International Neuropsychological Society, 2001, 7, 631-639.	1.2	448
61	Cortical Synapse Loss in progressive Supranuclear palsy. Journal of Neuropathology and Experimental Neurology, 2001, 60, 403-410.	0.9	52
62	Accuracy of clinical criteria for AD in the Honolulu–Asia Aging Study, a population-based study. Neurology, 2001, 57, 226-234.	1.5	135
63	Effect of Anti-inflammatory Medications on Neuropathological Findings in Alzheimer Disease. Archives of Neurology, 2001, 58, 517-a-518.	4.9	10
64	Preclinical Prediction of AD: Relation Between Neuropsychological and Neuroimaging Findings. , 0, , 97-110.		1
65	3-Hydroxy-3-methylglutaryl-coenzyme A reductase mRNA in Alzheimer and control brain. NeuroReport, 2001, 12, 2935-2938.	0.6	22
66	Update on the Neuropathological Diagnosis of Frontotemporal Dementias. Journal of Neuropathology and Experimental Neurology, 2001, 60, 1123-1126.	0.9	76
67	Neurofibrillary Degeneration: Patterns of Tau Isoform Expression. , 0, , 587-599.		1
68	Prevalence of Alzheimer's disease in very elderly people. Neurology, 2001, 56, 1690-1696.	1.5	195
69	Pathologic Correlates of Nondemented Aging, Mild Cognitive Impairment, and Early-Stage Alzheimer's Disease. Journal of Molecular Neuroscience, 2001, 17, 101-118.	1.1	449
70	Title is missing!. Journal of Radioanalytical and Nuclear Chemistry, 2001, 249, 443-447.	0.7	2
71	Altered subcellular distribution of transcriptional regulators in response to ${\rm A\hat{l}^2}$ peptide and during Alzheimer's disease. Mechanisms of Ageing and Development, 2001, 123, 11-20.	2.2	40
72	Relationship between beta amyloid peptide generating molecules and neprilysin in Alzheimer disease and normal brain. Brain Research, 2001, 919, 115-121.	1.1	204
73	Increased cAMP immunostaining in cerebral vessels in Alzheimer's disease. Brain Research, 2001, 922, 148-152.	1.1	22

#	ARTICLE	IF	CITATIONS
74	Neuron Number in the Entorhinal Cortex and CA1 in Preclinical Alzheimer Disease. Archives of Neurology, 2001, 58, 1395.	4.9	509
75	Ectopic White Matter Neurons, a Developmental Abnormality That May Be Caused by the <i> PSEN1 &lt; /i &gt; S169L Mutation in a Case of Familial AD with Myoclonus and Seizures. Journal of Neuropathology and Experimental Neurology, 2001, 60, 1137-1152.</i>	0.9	47
76	Ratio of 8-Hydroxyguanine in Intact DNA to Free 8-Hydroxyguanine Is Increased in Alzheimer Disease Ventricular Cerebrospinal Fluid. Archives of Neurology, 2001, 58, 392-6.	4.9	131
77	Alzheimer's disease: Its diagnosis and pathogenesis. International Review of Neurobiology, 2001, 48, 167-217.	0.9	17
78	Differing patterns of temporal atrophy in Alzheimer's disease and semantic dementia. Neurology, 2001, 57, 216-225.	1.5	537
79	Neuropathological Correlates of Dysarthria in Progressive Supranuclear Palsy. Archives of Neurology, 2001, 58, 265.	4.9	48
80	Pentagon copying is more impaired in dementia with Lewy bodies than in Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2001, 70, 483-488.	0.9	115
81	Recovery and Expression of Messenger RNA from Postmortem Human Brain Tissue. Modern Pathology, 2001, 14, 1157-1161.	2.9	63
82	Phases of $A\hat{l}^2$ -deposition in the human brain and its relevance for the development of AD. Neurology, 2002, 58, 1791-1800.	1.5	2,555
83	Patients with vascular dementia due to microvascular pathology have significant hippocampal neuronal loss. Journal of Neurology, Neurosurgery and Psychiatry, 2002, 72, 747-751.	0.9	116
84	Clinicopathological Validation Study of Four Sets of Clinical Criteria for Vascular Dementia. American Journal of Psychiatry, 2002, 159, 82-87.	4.0	193
85	High-Throughput Imaging of Brain Gene Expression. Genome Research, 2002, 12, 244-254.	2.4	49
86	Clinical and Neuropathological Characteristics of Hippocampal Sclerosis. Archives of Neurology, 2002, 59, 1099.	4.9	136
87	Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia. Neurology, 2002, 58, 750-757.	1.5	518
88	Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain, 2002, 125, 391-403.	3.7	587
89	Clinical correlates of selective pathology in the amygdala of patients with Parkinson's disease. Brain, 2002, 125, 2431-2445.	3.7	383
90	MRI measures of entorhinal cortex vs hippocampus in preclinical AD. Neurology, 2002, 58, 1188-1196.	1.5	505
91	Parkinson Disease Neuropathology. Archives of Neurology, 2002, 59, 102.	4.9	366

#	Article	IF	CITATIONS
92	Hippocampal volume as an index of Alzheimer neuropathology. Neurology, 2002, 58, 1476-1482.	1.5	308
93	$\hat{l}^2$ -Secretase Protein and Activity Are Increased in the Neocortex in Alzheimer Disease. Archives of Neurology, 2002, 59, 1381.	4.9	656
95	Research Evaluation and Prospective Diagnosis of Dementia With Lewy Bodies. Archives of Neurology, 2002, 59, 43.	4.9	137
96	Nonoverlapping but synergetic tau and APP pathologies in sporadic Alzheimer's disease. Neurology, 2002, 59, 398-407.	1.5	162
97	Office of Rare Diseases Neuropathologic Criteria for Corticobasal Degeneration. Journal of Neuropathology and Experimental Neurology, 2002, 61, 935-946.	0.9	592
98	Brain structure and cognition in a community sample of elderly Latinos. Neurology, 2002, 59, 383-391.	1.5	109
99	Two Types of Sporadic Cerebral Amyloid Angiopathy. Journal of Neuropathology and Experimental Neurology, 2002, 61, 282-293.	0.9	307
100	Progressive Reduction of Synaptophysin Message in Single Neurons in Alzheimer Disease. Journal of Neuropathology and Experimental Neurology, 2002, 61, 384-395.	0.9	52
101	Distinguishing Between Neurodegenerative Disease and Disease-Free Aging: Correlating Neuropsychological Evaluations and Neuropathological Studies in Centenarians. Psychosomatic Medicine, 2002, 64, 493-501.	1.3	102
102	Severe Involvement of Ambient Gyrus in Dementia with Grains. Journal of Neuropathology and Experimental Neurology, 2002, 61, 789-796.	0.9	50
103	Localization of $\hat{l}^2$ -Secretase Memapsin 2 in the Brain of Alzheimer's Patients and Normal Aged Controls. Experimental Neurology, 2002, 175, 10-22.	2.0	40
104	Tau Conformational Changes Correspond to Impairments of Episodic Memory in Mild Cognitive Impairment and Alzheimer's Disease. Experimental Neurology, 2002, 177, 475-493.	2.0	167
105	Neurofilament-Immunoreactive Neurons in Alzheimer's Disease and Dementia with Lewy Bodies. Neurobiology of Disease, 2002, 9, 249-257.	2.1	37
106	Inherited dementias. Neurologic Clinics, 2002, 20, 779-808.	0.8	12
107	Use of bomb pulse carbon-14 to age senile plaques and neurofibrillary tangles in Alzheimer's disease. Neurobiology of Aging, 2002, 23, 179-186.	1.5	30
108	Intracellular accumulation of β-amyloid1–42 in neurons is facilitated by the α7 nicotinic acetylcholine receptor in Alzheimer's disease. Neuroscience, 2002, 110, 199-211.	1.1	421
109	The Epidemiology of Alzheimer's Disease: An Update. , 0, , 205-208.		0
110	Familial Dementia With Lewy Bodies. Archives of Neurology, 2002, 59, 1622.	4.9	64

#	Article	IF	CITATIONS
111	Contributions of Other Brain Pathologies in Dementia with Lewy Bodies. Dementia and Geriatric Cognitive Disorders, 2002, 13, 130-148.	0.7	15
112	Involvement of microtubule integrity in memory impairment caused by colchicine. Pharmacology Biochemistry and Behavior, 2002, 71, 119-138.	1.3	59
113	Proteomic identification of oxidatively modified proteins in alzheimer's disease brain. part I: creatine kinase BB, glutamine synthase, and ubiquitin carboxy-terminal hydrolase L-1. Free Radical Biology and Medicine, 2002, 33, 562-571.	1.3	545
114	Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Annals of Neurology, 2002, 51, 145-155.	2.8	639
115	Striatal monoaminergic terminals in Lewy body and Alzheimer's dementias. Annals of Neurology, 2002, 51, 767-771.	2.8	38
116	Novel antibodies to synuclein show abundant striatal pathology in Lewy body diseases. Annals of Neurology, 2002, 52, 205-210.	2.8	300
117	Parkinson's disease and dementia with Lewy bodies: One disease or two?. Movement Disorders, 2002, 17, 1161-1165.	2.2	69
118	The Mini-Mental State exam may help in the differentiation of dementia with Lewy bodies and Alzheimer's disease. International Journal of Geriatric Psychiatry, 2002, 17, 503-509.	1.3	79
119	Loss of basal forebrain P75NTR immunoreactivity in subjects with mild cognitive impairment and Alzheimer's disease. Journal of Comparative Neurology, 2002, 443, 136-153.	0.9	195
120	Inverse association of Pin1 and tau accumulation in Alzheimer's disease hippocampus. Acta Neuropathologica, 2002, 104, 471-481.	3.9	77
121	Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part II: dihydropyrimidinase-related proteinâ€f2, α-enolase and heat shock cognateâ€f71. Journal of Neurochemistry, 2002, 82, 1524-1532.	2.1	528
122	Decrease in Peptide Methionine Sulfoxide Reductase in Alzheimer's Disease Brain. Journal of Neurochemistry, 2002, 73, 1660-1666.	2.1	232
123	Decreased estrogen receptor-? expression in hippocampal neurons in relation to hyperphosphorylated tau in Alzheimer patients. Acta Neuropathologica, 2003, 106, 213-220.	3.9	54
124	Wilms' tumor suppressor (WT1) is a mediator of neuronal degeneration associated with the pathogenesis of Alzheimer's disease. Brain Research, 2003, 983, 84-96.	1.1	36
125	Association of HFE mutations with neurodegeneration and oxidative stress in Alzheimer's disease and correlation with APOE. American Journal of Medical Genetics Part A, 2003, 119B, 48-53.	2.4	82
126	Caspase activation in the limbic cortex of subjects with early Alzheimer's disease. Annals of Neurology, 2003, 54, 393-398.	2.8	95
127	Proteomic identification of nitrated proteins in Alzheimer's disease brain. Journal of Neurochemistry, 2003, 85, 1394-1401.	2.1	514
128	Hippocampal sclerosis in a case of Alzheimer's disease-like dementia with late onset intractable epilepsy. European Journal of Neurology, 2003, 10, 333-334.	1.7	4

#	Article	IF	CITATIONS
129	Early-onset Alzheimer's disease with presenilin-1 M139V mutation: clinical, neuropsychological and neuropathological study. European Journal of Neurology, 2003, 10, 319-323.	1.7	32
130	2-dialkylamino-6-acylmalononitrile substituted naphthalenes (DDNP analogs): novel diagnostic and therapeutic tools in Alzheimer's disease. Molecular Imaging and Biology, 2003, 5, 404-417.	1.3	98
131	Apolipoprotein E isoform-specific regulation of dendritic spine morphology in apolipoprotein E transgenic mice and Alzheimer's disease patients. Neuroscience, 2003, 122, 305-315.	1.1	171
132	Subicular Dendritic Arborization in Alzheimer's Disease Correlates with Neurofibrillary Tangle Density. American Journal of Pathology, 2003, 163, 1615-1621.	1.9	76
133	Biomarkers of alzheimer's disease and mild cognitive impairment: are we there yet?. Experimental Neurology, 2003, 183, 7-10.	2.0	27
134	A grading system of Alzheimer disease lesions in neocortical areas. Neurobiology of Aging, 2003, 24, 563-572.	1.5	50
135	Antibodies against β-Amyloid Slow Cognitive Decline in Alzheimer's Disease. Neuron, 2003, 38, 547-554.	3.8	779
136	Neuroimaging in Alzheimer disease: an evidence-based review. Neuroimaging Clinics of North America, 2003, 13, 197-209.	0.5	193
137	Results of a high-resolution genome screen of 437 Alzheimer's Disease families. Human Molecular Genetics, 2003, 12, 23-32.	1.4	304
138	Neuropathological examination suggests impaired brain iron acquisition in restless legs syndrome. Neurology, 2003, 61, 304-309.	1.5	522
139	Lewy body cortical involvement may not always predict dementia in Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2003, 74, 852-856.	0.9	176
140	Neuropathologic Changes in Parkinson Disease With Late Onset of Dementia. Archives of Neurology, 2003, 60, 452.	4.9	7
141	Coexistent Lewy body disease in a case of "visual variant of Alzheimer's disease". Journal of Neurology, Neurosurgery and Psychiatry, 2003, 74, 389-389.	0.9	35
142	Genetic background regulates Â-amyloid precursor protein processing and Â-amyloid deposition in the mouse. Human Molecular Genetics, 2003, 12, 2949-2956.	1.4	82
143	Circle of Willis Atherosclerosis Is a Risk Factor for Sporadic Alzheimer's Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2003, 23, 2055-2062.	1.1	264
144	Influence of Alzheimer pathology on clinical diagnostic accuracy in dementia with Lewy bodies. Neurology, 2003, 60, 1586-1590.	1.5	290
145	Neurofibrillary Tangles, Amyloid, and Memory in Aging and Mild Cognitive Impairment. Archives of Neurology, 2003, 60, 729.	4.9	491
146	Survival in frontotemporal dementia. Neurology, 2003, 61, 349-354.	1.5	355

#	Article	IF	CITATIONS
147	Vascular Pathology in Alzheimer Disease: Correlation of Cerebral Amyloid Angiopathy and Arteriosclerosis/Lipohyalinosis with Cognitive Decline. Journal of Neuropathology and Experimental Neurology, 2003, 62, 1287-1301.	0.9	315
148	Stereologic Evidence for Persistence of Viable Neurons in Layer II of the Entorhinal Cortex and the CA1 Field in Alzheimer Disease. Journal of Neuropathology and Experimental Neurology, 2003, 62, 55-67.	0.9	67
149	Neuroimaging and Early Diagnosis of Alzheimer Disease: A Look to the Future. Radiology, 2003, 226, 315-336.	3.6	372
150	Alzheimer's disease with spastic paraparesis and 'cotton wool' plaques: two pedigrees with PS-1 exon 9 deletions. Brain, 2003, 126, 783-791.	3.7	51
151	Alzheimer Disease: Current Concepts and Emerging Diagnostic and Therapeutic Strategies. Annals of Internal Medicine, 2003, 138, 400.	2.0	119
152	Staging disease severity in pathologically confirmed cases of frontotemporal dementia. Neurology, 2003, 60, 1005-1011.	1.5	247
153	MRI-Guided SPECT Perfusion Measures and Volumetric MRI in Prodromal Alzheimer Disease. Archives of Neurology, 2003, 60, 1066.	4.9	75
154	Cortical and Leptomeningeal Cerebrovascular Amyloid and White Matter Pathology in Alzheimer's Disease. Molecular Medicine, 2003, 9, 112-122.	1.9	227
155	Cholinergic plasticity in hippocampus of individuals with mild cognitive impairment: Correlation with Alzheimer's neuropathology. Journal of Alzheimer's Disease, 2003, 5, 39-48.	1.2	129
156	Preservation of Brain Nerve Growth Factor in Mild Cognitive Impairment and Alzheimer Disease. Archives of Neurology, 2003, 60, 1143.	4.9	65
157	Dietary Fats and the Risk of Incident Alzheimer Diseaseâ€"Correction. Archives of Neurology, 2003, 60, 1072.	4.9	3
158	The importance of neuritic plaques and tangles to the development and evolution of AD. Neurology, 2004, 62, 1984-1989.	1.5	403
159	Down-regulation of DENN/MADD, a TNF receptor binding protein, correlates with neuronal cell death in Alzheimer's disease brain and hippocampal neurons. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 4210-4215.	3.3	121
160	Combining Correlated Diagnostic Tests: Application to Neuropathologic Diagnosis of Alzheimer's Disease. Medical Decision Making, 2004, 24, 659-669.	1.2	27
161	Atherosclerosis, vascular amyloidosis and brain hypoperfusion in the pathogenesis of sporadic Alzheimer's disease. Neurological Research, 2004, 26, 525-539.	0.6	154
162	Lewy Bodies in the Amygdala. Archives of Neurology, 2004, 61, 1915-9.	4.9	102
163	Neuropathologic Criteria for Diagnosing Alzheimer Disease in Persons with Pure Dementia of Alzheimer Type. Journal of Neuropathology and Experimental Neurology, 2004, 63, 1028-1037.	0.9	60
164	Neuropathological and Clinical Phenotype of an Italian Alzheimer Family with M239V Mutation of Presenilin 2 Gene. Journal of Neuropathology and Experimental Neurology, 2004, 63, 199-209.	0.9	39

#	Article	IF	CITATIONS
165	Right prosubiculum amyloid plaque density correlates with anosognosia in Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2004, 75, 1396-1400.	0.9	37
166	Cortical Lewy body disease. Journal of Neurology, Neurosurgery and Psychiatry, 2004, 75, 175-178.	0.9	15
167	Memory complaints in nondemented men predict future pathologic diagnosis of Alzheimer disease. Neurology, 2004, 63, 1960-1961.	1.5	66
168	Most cases of dementia with hippocampal sclerosis may represent frontotemporal dementia. Neurology, 2004, 63, 538-542.	1.5	83
169	Neuropathological diagnostic criteria for Alzheimer's disease. Neuropathology, 2004, 24, 254-260.	0.7	80
170	EEG findings in dementia with Lewy bodies causing diagnostic confusion with sporadic Creutzfeldt-Jakob disease. European Journal of Neurology, 2004, 11, 838-841.	1.7	40
171	Effect of Vascular Lesions on Cognition in Alzheimer's Disease: A Community-Based Study. Journal of the American Geriatrics Society, 2004, 52, 1442-1448.	1.3	107
172	Proteomics: a new approach to investigate oxidative stress in Alzheimer's disease brain. Brain Research, 2004, 1000, 1-7.	1.1	199
173	Overexpression of the human $\hat{l}^2$ -amyloid precursor protein downregulates cortistatin mRNA in PDAPP mice. Brain Research, 2004, 1023, 157-162.	1.1	13
174	Identification of families with cortical Lewy body disease. American Journal of Medical Genetics Part A, 2004, 128B, 118-122.	2.4	13
175	Clinicopathological correlates in frontotemporal dementia. Annals of Neurology, 2004, 56, 399-406.	2.8	549
176	Reduction of cortical TrkA but not p75NTR protein in early-stage Alzheimer's disease. Annals of Neurology, 2004, 56, 520-531.	2.8	181
177	Clinical, genetic, and neuropathologic characteristics of posterior cortical atrophy. Neurology, 2004, 63, 1168-1174.	1.5	554
178	Cerebrospinal Fluid Biomarkers for the Diagnosis of Alzheimer's Disease. , 2004, , 17-24.		0
179	Perineuronal nets potentially protect against oxidative stress. Experimental Neurology, 2004, 188, 309-315.	2.0	199
180	So what if tangles precede plaques?. Neurobiology of Aging, 2004, 25, 721-723.	1.5	31
181	Expression of the Small Heat-Shock Protein $\hat{l}\pm B$ -Crystallin in Tauopathies with Glial Pathology. American Journal of Pathology, 2004, 164, 155-166.	1.9	112
182	Positional effects of presenilin-1 mutations on tau phosphorylation in cortical plaques. Neurobiology of Disease, 2004, 15, 115-119.	2.1	33

#	Article	IF	CITATIONS
183	Hemorrhage is uncommon in new Alzheimer family with Flemish amyloid precursor protein mutation. Neurology, 2004, 63, 1613-1617.	1.5	35
184	Pathological Aging of the Brain. Topics in Magnetic Resonance Imaging, 2004, 15, 369-389.	0.7	60
186	Atherosclerosis of Cerebral Arteries in Alzheimer Disease. Stroke, 2004, 35, 2623-2627.	1.0	139
187	Increased proNGF Levels in Subjects with Mild Cognitive Impairment and Mild Alzheimer Disease. Journal of Neuropathology and Experimental Neurology, 2004, 63, 641-649.	0.9	212
188	Lewy Body-Related α-Synucleinopathy in Aging. Journal of Neuropathology and Experimental Neurology, 2004, 63, 742-749.	0.9	175
189	Unique Tauopathy in Fukuyama-Type Congenital Muscular Dystrophy. Journal of Neuropathology and Experimental Neurology, 2005, 64, 1118-1126.	0.9	9
190	Alpha-Synuclein and Chaperones in Dementia With Lewy Bodies. Journal of Neuropathology and Experimental Neurology, 2005, 64, 1058-1066.	0.9	55
191	Complement Activation in Very Early Alzheimer Disease. Alzheimer Disease and Associated Disorders, 2005, 19, 55-66.	0.6	99
192	Diminished taxol/GTP-stimulated tubulin polymerization in diseased region of brain from patients with late-onset or inherited Alzheimer's disease or frontotemporal dementia with parkinsonism linked to chromosome-17 but not individuals with mild cognitive impairment. Journal of Alzheimer's Disease, 2005, 8, 1-6.	1.2	8
193	Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: Link to brain reductions in acetylcholine. Journal of Alzheimer's Disease, 2005, 8, 247-268.	1.2	631
194	Predictors of Preclinical Alzheimer Disease and Dementia. Archives of Neurology, 2005, 62, 758.	4.9	190
195	Pramipexole vs Levodopa as Initial Treatment for Parkinson Disease: A 4-Year Randomized Controlled Trial—Correction. Archives of Neurology, 2005, 62, 430.	4.9	3
196	Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium. Neurology, 2005, 65, 1863-1872.	1.5	4,604
197	Expression of human FE65 in amyloid precursor protein transgenic mice is associated with a reduction in l²-amyloid load. Journal of Neurochemistry, 2005, 93, 330-338.	2.1	45
198	Precursor form of brain-derived neurotrophic factor and mature brain-derived neurotrophic factor are decreased in the pre-clinical stages of Alzheimer's disease. Journal of Neurochemistry, 2005, 93, 1412-1421.	2.1	614
199	Antemortem diagnosis of frontotemporal lobar degeneration. Annals of Neurology, 2005, 57, 480-488.	2.8	181
200	Lipid peroxidation is an early event in the brain in amnestic mild cognitive impairment. Annals of Neurology, 2005, 58, 730-735.	2.8	264
201	Neuropathology of dementia in Parkinson's disease: A prospective, community-based study. Annals of Neurology, 2005, 58, 773-776.	2.8	312

#	Article	IF	CITATIONS
202	Abnormal accumulation of citrullinated proteins catalyzed by peptidylarginine deiminase in hippocampal extracts from patients with Alzheimer's disease. Journal of Neuroscience Research, 2005, 80, 120-128.	1.3	215
203	Staging disease severity in movement disorder tauopathies: Brain atrophy separates progressive supranuclear palsy from corticobasal degeneration. Movement Disorders, 2005, 20, 34-39.	2.2	22
204	Increased tau burden in the cortices of progressive supranuclear palsy presenting with corticobasal syndrome. Movement Disorders, 2005, 20, 982-988.	2.2	111
206	Speaking the Language of Genetics: A Primer. Journal of Midwifery and Women's Health, 2005, 50, 184-188.	0.7	3
207	Apolipoprotein E co-localizes with newly formed amyloid $\hat{l}^2$ -protein (A $\hat{l}^2$ ) deposits lacking immunoreactivity against N-terminal epitopes of A $\hat{l}^2$ in a genotype-dependent manner. Acta Neuropathologica, 2005, 110, 459-471.	3.9	50
208	Insoluble α-synuclein in alzheimer's disease without lewy body formation. Neurotoxicity Research, 2005, 7, 69-76.	1.3	10
209	Problems Associated with Biological Markers of Alzheimer's Disease. Neurochemical Research, 2005, 30, 1501-1510.	1.6	34
210	Personality Change Precedes Clinical Diagnosis of Dementia of the Alzheimer Type. Journals of Gerontology - Series B Psychological Sciences and Social Sciences, 2005, 60, P98-P101.	2.4	122
211	Hemorrhagic infarction in white matter following acute carbon monoxide poisoning. Neurology, 2005, 64, 1101-1101.	1.5	4
212	Verbal and visuospatial deficits in dementia with Lewy bodies. Neurology, 2005, 65, 1232-1238.	1.5	86
213	Genetic association between the <i>APOE</i> * <i>4</i> allele and Lewy bodies in Alzheimer disease. Neurology, 2005, 64, 509-513.	1.5	48
214	MRI predictors of risk of incident Alzheimer disease: A longitudinal study. Neurology, 2005, 64, 1520-1524.	1.5	185
215	Proteomic determination of widespread detergent insolubility, including $\hat{A^2}$ but not tau, early in the pathogenesis of Alzheimer's disease. FASEB Journal, 2005, 19, 1923-1925.	0.2	46
216	Evidence of increased oxidative damage in subjects with mild cognitive impairment. Neurology, 2005, 64, 1152-1156.	1.5	488
217	Most cases of dementia with hippocampal sclerosis may represent frontotemporal dementia. Neurology, 2005, 64, 1102-1102.	1.5	33
218	Frontotemporal Lobar Degeneration. Archives of Neurology, 2005, 62, 925-30.	4.9	354
219	Sex Differences in the Clinical Manifestations of Alzheimer Disease Pathology. Archives of General Psychiatry, 2005, 62, 685.	13.8	455
220	Reduction of Choline Acetyltransferase Activity in Primary Visual Cortex in Mild to Moderate Alzheimer's Disease. Archives of Neurology, 2005, 62, 425.	4.9	70

#	Article	IF	CITATIONS
221	The evolution and pathology of frontotemporal dementia. Brain, 2005, 128, 1996-2005.	3.7	585
222	Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions. Neurology, 2005, 64, 834-841.	1.5	490
223	Apolipoprotein E Genotype Regulates Amyloid-Â Cytotoxicity. Journal of Neuroscience, 2005, 25, 3621-3627.	1.7	52
224	Changing Patient Characteristics and Survival Experience in an Alzheimer's Center Patient Cohort. Dementia and Geriatric Cognitive Disorders, 2005, 20, 198-208.	0.7	52
225	Cognitive aging and Alzheimer's disease. Postgraduate Medical Journal, 2005, 81, 343-352.	0.9	29
226	Presenilin 1 Glu318Gly Polymorphism. Archives of Neurology, 2005, 62, 1624-7.	4.9	11
227	Physicochemical characteristics of soluble oligomeric $\hat{Al^2}$ and their pathologic role in Alzheimer's disease. Neurological Research, 2005, 27, 869-881.	0.6	113
228	From The Cover: Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 2273-2276.	3.3	790
229	Relationship between Parkinson disease with dementia and dementia with Lewy bodies. Parkinsonism and Related Disorders, 2005, 11, 305-309.	1.1	17
230	Molecular, Structural, and Functional Characterization of Alzheimer's Disease: Evidence for a Relationship between Default Activity, Amyloid, and Memory. Journal of Neuroscience, 2005, 25, 7709-7717.	1.7	1,839
231	Accumulation of Amyloid Precursor Protein in the Mitochondrial Import Channels of Human Alzheimer's Disease Brain Is Associated with Mitochondrial Dysfunction. Journal of Neuroscience, 2006, 26, 9057-9068.	1.7	708
232	Pathological Heterogeneity of Frontotemporal Lobar Degeneration with Ubiquitin-Positive Inclusions Delineated by Ubiquitin Immunohistochemistry and Novel Monoclonal Antibodies. American Journal of Pathology, 2006, 169, 1343-1352.	1.9	296
233	Body mass index in older persons is associated with Alzheimer disease pathology. Neurology, 2006, 67, 1949-1954.	1.5	112
234	Alzheimer neuropathology in nondemented aging: Keeping mind over matter. Neurology, 2006, 66, 1801-1802.	1.5	10
235	Age-related neuropathology, cognitive decline, and Alzheimer's disease. Ageing Research Reviews, 2006, 5, 1-13.	5.0	134
236	Lack of association of two chromosome 10q24 SNPs with Alzheimer's disease. Neuroscience Letters, 2006, 408, 170-172.	1.0	5
237	Beta-site APP cleaving enzyme 1 (BACE1) is increased in remaining neurons in Alzheimer's disease brains. Neuroscience Research, 2006, 54, 24-29.	1.0	59
238	Differences in regional brain atrophy in genetic forms of Alzheimer's disease. Neurobiology of Aging, 2006, 27, 387-393.	1.5	31

#	Article	IF	CITATIONS
239	Isolation of neural precursor cells from Alzheimer's disease and aged control postmortem brain. Neurobiology of Aging, 2006, 27, 909-917.	1.5	49
240	Aβ Species Removal After Aβ < sub>42 < /sub>1 mmunization. Journal of Neuropathology and Experimental Neurology, 2006, 65, 1040-1048.	0.9	260
241	The Neuropathology of Alzheimer Disease in African American and White Individuals. Archives of Neurology, 2006, 63, 87.	4.9	36
242	Preliminary demonstration of an allelic association of the IREB2 gene with Alzheimer's disease. Journal of Alzheimer's Disease, 2006, 9, 225-233.	1.2	21
243	Physiopathologie de la maladie d'Alzheimer. EMC - Traité De Médecine AKOS, 2006, 1, 1-11.	0.0	0
244	Laboratory Diagnosis of Dementia. Laboratory Medicine, 2006, 37, 362-365.	0.8	1
245	Interlaboratory Comparison of Assessments of Alzheimer Disease-Related Lesions: A Study of the BrainNet Europe Consortium. Journal of Neuropathology and Experimental Neurology, 2006, 65, 740-757.	0.9	95
246	Endoplasmic Reticulum Stress Features Are Prominent in Alzheimer Disease but Not in Prion Diseases In Vivo. Journal of Neuropathology and Experimental Neurology, 2006, 65, 348-357.	0.9	196
247	Argyrophilic Grain Disease in Demented Subjects Presenting Initially With Amnestic Mild Cognitive Impairment. Journal of Neuropathology and Experimental Neurology, 2006, 65, 602-609.	0.9	48
248	PROGRESS IN CLINICAL NEUROSCIENCES: Canadian Guidelines for the Development of Antidementia Therapies: A Conceptual Summary. Canadian Journal of Neurological Sciences, 2006, 33, 6-26.	0.3	17
249	Increased Metabolic Activity in Nucleus Basalis of Meynert Neurons in Elderly Individuals With Mild Cognitive Impairment as Indicated by the Size of the Golgi Apparatus. Journal of Neuropathology and Experimental Neurology, 2006, 65, 257-266.	0.9	25
250	Atypical Protein Kinase C in Neurodegenerative Disease I. Journal of Neuropathology and Experimental Neurology, 2006, 65, 319-326.	0.9	49
251	Genetic Epidemiology of Alzheimer Disease. Alzheimer Disease and Associated Disorders, 2006, 20, S58-S62.	0.6	18
252	S14 TRANSGENIC MICE MODELS FOR ALZHEIMER??S DISEASE. Behavioural Pharmacology, 2006, 17, 538-539.	0.8	1
253	Lewy Body Pathology in Familial Alzheimer Disease. Archives of Neurology, 2006, 63, 370.	4.9	122
254	Molecular indices of oxidative stress and mitochondrial dysfunction occur early and often progress with severity of Alzheimer's disease. Journal of Alzheimer's Disease, 2006, 9, 167-181.	1.2	277
255	$\hat{l}^2$ -Amyloid treatment of two complementary P301L tau-expressing Alzheimer's disease models reveals similar deregulated cellular processes. Proteomics, 2006, 6, 6566-6577.	1.3	62
256	Dementia with Lewy Bodies. A Distinct Nonâ€Alzheimer Dementia Syndrome?. Brain Pathology, 1998, 8, 299-324.	2.1	96

#	Article	IF	CITATIONS
257	Establishing a Pathological Diagnosis in Degenerative Dementias. Brain Pathology, 1998, 8, 403-406.	2.1	46
258	Lewy Bodies in Alzheimer's Disease: A Neuropathological Review of 145 Cases Using αâ€ <b>S</b> ynuclein Immunohistochemistry. Brain Pathology, 2000, 10, 378-384.	2.1	612
259	Excitatory Amino Acid Transporter EAATâ€2 in Tangleâ€bearing Neurons in Alzheimer's Disease. Brain Pathology, 2002, 12, 405-411.	2.1	43
260	Characteristics of alpha-synucleinopathy in centenarians. Acta Neuropathologica, 2006, 111, 450-458.	3.9	48
261	Argyrophilic grain disease: frequency and neuropathology in centenarians. Acta Neuropathologica, 2006, 111, 320-328.	3.9	41
262	Relapsing polychondritis with features of dementia with Lewy bodies. Acta Neuropathologica, 2006, 112, 217-225.	3.9	13
263	Population-based neuropathological studies of dementia: design, methods and areas of investigation – a systematic review. BMC Neurology, 2006, 6, 2.	0.8	97
264	Coxibs and Alzheimer's disease: Should they stay or should they go?. Annals of Neurology, 2006, 59, 219-228.	2.8	51
265	Frontotemporal dementia: Clinicopathological correlations. Annals of Neurology, 2006, 59, 952-962.	2.8	444
266	Cognitive impact of subcortical vascular and Alzheimer's disease pathology. Annals of Neurology, 2006, 60, 677-687.	2.8	236
267	Early frontotemporal dementia targets neurons unique to apes and humans. Annals of Neurology, 2006, 60, 660-667.	2.8	291
268	Novel Ubiquitin Neuropathology in Frontotemporal Dementia With <i>Valosin-Containing Protein</i> Gene Mutations. Journal of Neuropathology and Experimental Neurology, 2006, 65, 571-581.	0.9	206
269	Comparative proteomics of cerebrospinal fluid in neuropathologically-confirmed Alzheimer's disease and non-demented elderly subjects. Neurological Research, 2006, 28, 155-163.	0.6	188
270	Biochemical Staging of Synucleinopathy and Amyloid Deposition in Dementia With Lewy Bodies. Journal of Neuropathology and Experimental Neurology, 2006, 65, 278-288.	0.9	95
271	Elevated Zinc Transporter-6 in Mild Cognitive Impairment, Alzheimer Disease, and Pick Disease. Journal of Neuropathology and Experimental Neurology, 2006, 65, 489-498.	0.9	43
272	Neuropathologic Outcome of Mild Cognitive Impairment Following Progression to Clinical Dementia. Archives of Neurology, 2006, 63, 674.	4.9	377
273	Differential Expression of Synaptic Proteins in the Frontal and Temporal Cortex of Elderly Subjects With Mild Cognitive Impairment. Journal of Neuropathology and Experimental Neurology, 2006, 65, 592-601.	0.9	183
274	Decision Rules Guiding the Clinical Diagnosis of Alzheimer's Disease in Two Community-Based Cohort Studies Compared to Standard Practice in a Clinic-Based Cohort Study. Neuroepidemiology, 2006, 27, 169-176.	1.1	302

#	ARTICLE	IF	CITATIONS
275	What best differentiates Lewy body from Alzheimer's disease in early-stage dementia?. Brain, 2006, 129, 729-735.	3.7	235
276	Rates of cerebral atrophy differ in different degenerative pathologies. Brain, 2006, 130, 1148-1158.	3.7	146
277	Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology, 2006, 66, 1837-1844.	1.5	1,097
278	Alzheimer's Disease. Seminars in Neurology, 2006, 26, 499-506.	0.5	50
279	PINK1 protein in normal human brain and Parkinson's disease. Brain, 2006, 129, 1720-1731.	3.7	291
280	Visualizing Pathology Deposits in the Living Brain of Patients with Alzheimer's Disease. Methods in Enzymology, 2006, 412, 144-160.	0.4	44
281	Lewy bodies in the amygdala increase risk for major depression in subjects with Alzheimer disease. Neurology, 2006, 67, 660-665.	1.5	36
282	Survival and mortality differences between dementia with Lewy bodies vs Alzheimer disease. Neurology, 2006, 67, 1935-1941.	1.5	207
283	Memory complaints are related to Alzheimer disease pathology in older persons. Neurology, 2006, 67, 1581-1585.	1.5	172
284	Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology. Journal of Psychopharmacology, 2006, 20, 732-755.	2.0	145
285	Xâ€34 Labeling of Abnormal Protein Aggregates During the Progression of Alzheimer's Disease. Methods in Enzymology, 2006, 412, 123-144.	0.4	52
286	Predicting Lewy Body Pathology in a Community-Based Sample With Clinical Diagnosis of Alzheimer's Disease. Journal of Geriatric Psychiatry and Neurology, 2006, 19, 195-201.	1.2	20
287	Clinical phenotype of Parkinson disease dementia. Neurology, 2006, 67, 1605-1611.	1.5	222
288	Brain metal concentrations in chronic liver failure patients with pallidal T1 MRI hyperintensity. Neurology, 2006, 67, 1984-1989.	1.5	87
289	Mild Cognitive Impairment Is Early-Stage Alzheimer Disease. Archives of Neurology, 2006, 63, 15.	4.9	160
290	Galanin Fiber Hypertrophy within the Cholinergic Nucleus Basalis during the Progression of Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders, 2006, 21, 205-214.	0.7	40
291	Increased Neurofibrillary Tangles in the Brains of Older Pedestrians Killed in Traffic Accidents.  Dementia and Geriatric Cognitive Disorders, 2006, 22, 20-26.	0.7	19
292	Focally Elevated Creatine Detected in Amyloid Precursor Protein (APP) Transgenic Mice and Alzheimer Disease Brain Tissue. Journal of Biological Chemistry, 2006, 281, 5-8.	1.6	67

#	Article	IF	CITATIONS
293	CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain, 2006, 129, 3035-3041.	3.7	541
294	Selectively increased oxidative modifications mapped to detergentâ€insoluble forms of Aβ and βâ€ill tubulin in Alzheimer's disease. FASEB Journal, 2006, 20, 1473-1483.	0.2	29
295	GGA1 Is Expressed in the Human Brain and Affects the Generation of Amyloid Â-Peptide. Journal of Neuroscience, 2006, 26, 12838-12846.	1.7	82
296	<i>In Vitro</i> Characterization of Pittsburgh Compound-B Binding to Lewy Bodies. Journal of Neuroscience, 2007, 27, 10365-10371.	1.7	154
297	Neuropathology and treatment of Alzheimer disease: did we lose the forest for the trees?. Expert Review of Neurotherapeutics, 2007, 7, 473-485.	1.4	41
298	Hippocampal and entorhinal atrophy in mild cognitive impairment: Prediction of Alzheimer disease. Neurology, 2007, 68, 828-836.	1.5	649
299	Clinicopathological concordance and discordance in three monozygotic twin pairs with familial Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2007, 78, 1050-1055.	0.9	42
300	TDP-43 Pathologic Lesions and Clinical Phenotype in Frontotemporal Lobar Degeneration With Ubiquitin-Positive Inclusions. Archives of Neurology, 2007, 64, 1449.	4.9	61
301	Cortical biochemistry in MCI and Alzheimer disease: Lack of correlation with clinical diagnosis. Neurology, 2007, 68, 757-763.	1.5	54
302	A novel progranulin mutation associated with variable clinical presentation and tau, TDP43 and alpha-synuclein pathology. Brain, 2007, 130, 1360-1374.	3.7	124
303	A novel locus for dementia with Lewy bodies: a clinically and genetically heterogeneous disorder. Brain, 2007, 130, 2277-2291.	3.7	56
304	Clinical Prediction of Alzheimer Disease Dementia Across the Spectrum of Mild Cognitive Impairment. Archives of General Psychiatry, 2007, 64, 1443.	13.8	148
305	Neuropathological changes in essential tremor: 33 cases compared with 21 controls. Brain, 2007, 130, 3297-3307.	3.7	523
306	Personality traits distinguishing dementia with Lewy bodies from Alzheimer disease. Neurology, 2007, 68, 1895-1901.	1.5	38
307	Clinical and Psychometric Distinction of Frontotemporal and Alzheimer Dementias. Archives of Neurology, 2007, 64, 535.	4.9	66
308	Early-Onset Alzheimer's Disease Is Associated With Greater Pathologic Burden. Journal of Geriatric Psychiatry and Neurology, 2007, 20, 29-33.	1.2	108
309	What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia?. Neurology, 2007, 69, 871-877.	1.5	271
310	Neuropsychological Comparison of Alzheimer's Disease and Dementia with Lewy Bodies. Dementia and Geriatric Cognitive Disorders, 2007, 23, 120-125.	0.7	42

#	Article	IF	CITATIONS
311	Clinical Characteristics of Dementia Associated with Argyrophilic Grain Disease. Dementia and Geriatric Cognitive Disorders, 2007, 24, 229-234.	0.7	14
313	Education delays accelerated decline on a memory test in persons who develop dementia. Neurology, 2007, 69, 1657-1664.	1.5	209
314	Chapter 3 Mild Cognitive Impairment. Blue Books of Neurology, 2007, , 59-87.	0.1	2
315	Clinical, Genetic, and Pathologic Characteristics of Patients With Frontotemporal Dementia and Progranulin Mutations. Archives of Neurology, 2007, 64, 1148.	4.9	52
316	The Genetics of Very Early Onset Alzheimer Disease. Cognitive and Behavioral Neurology, 2007, 20, 149-156.	0.5	46
317	Plasma Aβ Levels Do Not Reflect Brain Aβ Levels. Journal of Neuropathology and Experimental Neurology, 2007, 66, 264-271.	0.9	62
318	The enigma of mixed dementia., 2007, 3, 40-53.		111
319	A chapter in the development of Alzheimer's disease research: A case study of public policies on the development and funding of research programs., 2007, 3, 243-258.		19
320	TDP-43 in Familial and Sporadic Frontotemporal Lobar Degeneration with Ubiquitin Inclusions. American Journal of Pathology, 2007, 171, 227-240.	1.9	446
321	Oxidative DNA damage in mild cognitive impairment and late-stage Alzheimer's disease. Nucleic Acids Research, 2007, 35, 7497-7504.	6.5	433
322	Clinicopathological Findings of Suicide in the Elderly: Three Cases. Suicide and Life-Threatening Behavior, 2007, 37, 648-658.	0.9	13
323	Redox-reactive autoantibodies in Alzheimer's patients' cerebrospinal fluids: Preliminary studies. Autoimmunity, 2007, 40, 390-396.	1.2	11
324	FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease. Brain, 2007, 130, 2616-2635.	3.7	508
325	Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology, 2007, 69, 2197-2204.	1.5	1,513
326	Quantitative Proteomics Identifies Surfactant-Resistant $\hat{l}_{\pm}$ -Synuclein in Cerebral Cortex of Parkinsonism-Dementia Complex of Guam but Not Alzheimer's Disease or Progressive Supranuclear Palsy. American Journal of Pathology, 2007, 171, 993-1002.	1.9	23
327	Neurodegeneration., 2007, , 193-228.		4
328	Dissociation of Neuropathologic Findings and Cognition. Archives of Neurology, 2007, 64, 1193.	4.9	29
329	Clinicopathological correlates of Alzheimer's disease in a general autopsy series from Brazil. Dementia E Neuropsychologia, 2007, 1, 356-360.	0.3	2

#	Article	IF	CITATIONS
330	Clinical evaluation of patients with moderate to severe Alzheimer disease. Dementia E Neuropsychologia, 2007, 1, 296-302.	0.3	0
331	Kalirin is Under-Expressed in Alzheimer's Disease Hippocampus. Journal of Alzheimer's Disease, 2007, 11, 385-397.	1.2	64
332	Pathological correlates of dementia in a longitudinal, populationâ€based sample of aging. Annals of Neurology, 2007, 62, 406-413.	2.8	380
333	Discovery of (S)-2-((S)-2-(3,5-difluorophenyl)-2-hydroxyacetamido)-N-((S,Z)-3-methyl-4-oxo-4,5-dihydro-3H-benzo[d][1,2]diaze (BMS-433796): A γ-secretase inhibitor with Aβ lowering activity in a transgenic mouse model of Alzheimer's disease. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 4006-4011.	epin-5-yl)pı 1.0	roganamide
334	Lewy body variant of Alzheimer's disease or cerebral type Lewy body disease? Two autopsy cases of presenile onset with minimal involvement of the brainstem. Neuropathology, 2007, 27, 21-35.	0.7	25
335	Neuropathology of mild cognitive impairment. Neuropathology, 2007, 27, 578-584.	0.7	80
336	$\hat{Al^2}$ peptides can enter the brain through a defective bloodâ $\in$ "brain barrier and bind selectively to neurons. Brain Research, 2007, 1142, 223-236.	1.1	120
337	Brain bank of the Brazilian aging brain study group—a milestone reached and more than 1,600 collected brains. Cell and Tissue Banking, 2007, 8, 151-162.	0.5	125
338	Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathologica, 2007, 114, 5-22.	3.9	978
339	Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases. Acta Neuropathologica, 2007, 114, 221-229.	3.9	378
340	Tracing of temporo-entorhinal connections in the human brain: cognitively impaired argyrophilic grain disease cases show dendritic alterations but no axonal disconnection of temporo-entorhinal association neurons. Acta Neuropathologica, 2008, 115, 175-183.	3.9	13
341	The progression of pathology in longitudinally followed patients with Parkinson's disease. Acta Neuropathologica, 2008, 115, 409-415.	3.9	337
342	Cerebral amyloid angiopathy and its relationship to Alzheimer's disease. Acta Neuropathologica, 2008, 115, 599-609.	3.9	288
343	Synthesis of a [ <sup>18</sup> F]fluorobenzothiazole as potential amyloid imaging agent. Journal of Labelled Compounds and Radiopharmaceuticals, 2008, 51, 137-145.	0.5	14
344	Neuropathological basis of magnetic resonance images in aging and dementia. Annals of Neurology, 2008, 63, 72-80.	2.8	282
345	Frequency and course of mild cognitive impairment in a multiethnic community. Annals of Neurology, 2008, 63, 494-506.	2.8	486
346	Clinicopathological Outline of Dementia with Lewy Bodies Applying the Revised Criteria: The Hisayama Study. Brain Pathology, 2008, 18, 317-325.	2.1	71
347	Parenchymal and vascular Aβâ€deposition and its effects on the degeneration of neurons and cognition in Alzheimer's disease. Journal of Cellular and Molecular Medicine, 2008, 12, 1848-1862.	1.6	109

#	Article	IF	CITATIONS
348	Endoplasmic Reticulum Stress in Disease Pathogenesis. Annual Review of Pathology: Mechanisms of Disease, 2008, 3, 399-425.	9.6	637
349	Dementia of the Alzheimer Type. Epidemiologic Reviews, 2008, 30, 15-34.	1.3	126
350	Feature Extraction and Strategy of Analyzing Structural Neuroimaging in Dementia. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2008, 89, 75-86.	1.0	1
351	Accuracy of dementia diagnosisa direct comparison between radiologists and a computerized method. Brain, 2008, 131, 2969-2974.	3.7	222
352	Alzheimer Disease Pathology As a Host Response. Journal of Neuropathology and Experimental Neurology, 2008, 67, 523-531.	0.9	150
353	Relationships Between Expression of Apolipoprotein E and $\hat{l}^2$ -Amyloid Precursor Protein Are Altered in Proximity to Alzheimer $\hat{l}^2$ -Amyloid Plaques. Journal of Neuropathology and Experimental Neurology, 2008, 67, 773-783.	0.9	21
354	Role of the Neuropathology of Alzheimer Disease in Dementia in the Oldest-Old. Archives of Neurology, 2008, 65, 1211-7.	4.9	142
355	Genetic aspects of Alzheimer disease. Genetics in Medicine, 2008, 10, 231-239.	1.1	232
356	F2-Dihomo-isoprostanes arise from free radical attack on adrenic acid. Journal of Lipid Research, 2008, 49, 995-1005.	2.0	66
357	A novel <i>PSEN2</i> mutation associated with a peculiar phenotype. Neurology, 2008, 70, 1549-1554.	1.5	62
358	Cognitive profiles in dementia. Neurology, 2008, 71, 1783-1789.	1.5	62
359	Distinct MRI Atrophy Patterns in Autopsy-Proven Alzheimer's Disease and Frontotemporal Lobar Degeneration. American Journal of Alzheimer's Disease and Other Dementias, 2008, 22, 474-488.	0.9	232
360	An aberrant protein complex in CSF as a biomarker of Alzheimer disease. Neurology, 2008, 70, 2212-2218.	1.5	31
361	Nature or nurture. Neurology, 2008, 70, 1725-1727.	1.5	4
362	Automatic classification of MR scans in Alzheimer's disease. Brain, 2008, 131, 681-689.	3.7	1,017
363	Incidence and survival of dementia in a general population of Japanese elderly: the Hisayama study. Journal of Neurology, Neurosurgery and Psychiatry, 2008, 80, 366-370.	0.9	94
364	Education, cognitive function, and severity of neuropathology in Alzheimer disease. Neurology, 2008, 70, 1732-1739.	1.5	91
365	Altered neuronal gene expression in brain regions differentially affected by Alzheimer's disease: a reference data set. Physiological Genomics, 2008, 33, 240-256.	1.0	264

#	Article	IF	CITATIONS
366	MRI correlates of neurofibrillary tangle pathology at autopsy. Neurology, 2008, 71, 743-749.	1.5	312
367	Progressive aphasia secondary to Alzheimer disease vs FTLD pathology. Neurology, 2008, 70, 25-34.	1.5	143
368	Update on Recent Molecular and Genetic Advances in Frontotemporal Lobar Degeneration. Journal of Neuropathology and Experimental Neurology, 2008, 67, 635-648.	0.9	32
369	Incidence and Extent of Lewy Body-Related α-Synucleinopathy in Aging Human Olfactory Bulb. Journal of Neuropathology and Experimental Neurology, 2008, 67, 1072-1083.	0.9	117
370	Interaction of Neuritic Plaques and Education Predicts Dementia. Alzheimer Disease and Associated Disorders, 2008, 22, 188-193.	0.6	28
372	Risk Factors for Dementia of Alzheimer Type and Aging-Associated Cognitive Decline in a Spanish Population Based Sample, and in Brains with Pathology Confirmed Alzheimer's Disease. Journal of Alzheimer's Disease, 2008, 14, 179-191.	1.2	6
373	Evidence that Non-Fibrillar Tau Causes Pathology Linked to Neurodegeneration and Behavioral Impairments. Journal of Alzheimer's Disease, 2008, 14, 393-399.	1.2	106
374	Elevated levels of 4-hydroxynonenal-histidine Michael adduct in the hippocampi of patients with Alzheimer's disease. Biomedical Research, 2009, 30, 227-233.	0.3	56
376	The Neuropathology of Older Persons with and Without Dementia from Community versus Clinic Cohorts. Journal of Alzheimer's Disease, 2009, 18, 691-701.	1.2	292
377	Neuropathology-Based Risk Scoring for Dementia Diagnosis in the Elderly. Journal of Alzheimer's Disease, 2009, 17, 875-885.	1.2	13
378	Apolipoprotein E $\hat{l}\mu4$ is associated with disease-specific effects on brain atrophy in Alzheimer's disease and frontotemporal dementia. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 2018-2022.	3.3	154
379	Twin pairs discordant for neuropathologically confirmed Lewy body dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2009, 80, 562-565.	0.9	20
380	Cognitive Decline in Alzheimer's Disease Is Associated with Selective Changes in Calcineurin/NFAT Signaling. Journal of Neuroscience, 2009, 29, 12957-12969.	1.7	255
381	Cortical $\hat{l}\pm7$ Nicotinic Acetylcholine Receptor and $\hat{l}^2$ -Amyloid Levels in Early Alzheimer Disease. Archives of Neurology, 2009, 66, 646-51.	4.9	59
382	Reduction of SorLA/LR11, a Sorting Protein Limiting $\hat{l}^2$ -Amyloid Production, in Alzheimer Disease Cerebrospinal Fluid. Archives of Neurology, 2009, 66, 448-57.	4.9	79
383	Cerebrospinal Fluid $\hat{l}^2$ -Amyloid 42 and Tau Proteins as Biomarkers of Alzheimer-Type Pathologic Changes in the Brain. Archives of Neurology, 2009, 66, 382-9.	4.9	747
384	Brains With Medial Temporal Lobe Neurofibrillary Tangles But No Neuritic Amyloid Plaques Are a Diagnostic Dilemma But May Have Pathogenetic Aspects Distinct From Alzheimer Disease. Journal of Neuropathology and Experimental Neurology, 2009, 68, 774-784.	0.9	92
385	Absence of Pittsburgh Compound B Detection of Cerebral Amyloid $\hat{l}^2$ in a Patient With Clinical, Cognitive, and Cerebrospinal Fluid Markers of Alzheimer Disease. Archives of Neurology, 2009, 66, 1557-62.	4.9	188

#	Article	IF	Citations
386	APOE $\hat{l}\mu2$ is associated with intact cognition but increased Alzheimer pathology in the oldest old. Neurology, 2009, 72, 829-834.	1.5	178
387	Epidemiological Pathology of Dementia: Attributable-Risks at Death in the Medical Research Council Cognitive Function and Ageing Study. PLoS Medicine, 2009, 6, e1000180.	3.9	238
388	Clinical syndromes associated with posterior atrophy. Neurology, 2009, 73, 1571-1578.	1.5	233
389	Relative preservation of MMSE scores in autopsy-proven dementia with Lewy bodies. Neurology, 2009, 73, 1127-1133.	1.5	82
390	Neuropathologic intermediate phenotypes enhance association to Alzheimer susceptibility alleles. Neurology, 2009, 72, 1495-1503.	1.5	83
391	<i>PRESENILIN1</i> G217R MUTATION LINKED TO ALZHEIMER DISEASE WITH COTTON WOOL PLAQUES. Neurology, 2009, 73, 480-482.	1.5	10
392	Declining brain glucose metabolism in normal individuals with a maternal history of Alzheimer disease. Neurology, 2009, 72, 513-520.	1.5	179
393	Memory performance is related to amyloid and tau pathology in the hippocampus. Journal of Neurology, Neurosurgery and Psychiatry, 2009, 80, 715-721.	0.9	30
394	Longitudinal Study of the Transition From Healthy Aging to Alzheimer Disease. Archives of Neurology, 2009, 66, 1254-9.	4.9	253
395	Proteomic identification of nitrated brain proteins in early Alzheimer's disease inferior parietal lobule. Journal of Cellular and Molecular Medicine, 2009, 13, 2019-2029.	1.6	111
396	Altered expression of claudin family proteins in Alzheimer's disease and vascular dementia brains. Journal of Cellular and Molecular Medicine, 2009, 14, no-no.	1.6	45
397	The neuropathology of probable Alzheimer disease and mild cognitive impairment. Annals of Neurology, 2009, 66, 200-208.	2.8	745
398	Cytomorphologic manifestations of Alzheimer's disease using brain squash smears: An autopsy study with histology–cytology correlation. Diagnostic Cytopathology, 2009, 37, 654-660.	0.5	2
399	Torpedoes in Parkinson's disease, Alzheimer's disease, essential tremor, and control brains. Movement Disorders, 2009, 24, 1600-1605.	2.2	78
400	Evidence of angiogenic vessels in Alzheimer's disease. Journal of Neural Transmission, 2009, 116, 587-597.	1.4	126
401	Olfactory bulb α-synucleinopathy has high specificity and sensitivity for Lewy body disorders. Acta Neuropathologica, 2009, 117, 169-74.	3.9	193
402	Classification and basic pathology of Alzheimer disease. Acta Neuropathologica, 2009, 118, 5-36.	3.9	805
403	Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction. Acta Neuropathologica, 2009, 117, 613-634.	3.9	553

#	Article	IF	Citations
404	FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 811-822.	3.3	409
405	The dorsal raphe nucleus shows phosphoâ€tau neurofibrillary changes before the transentorhinal region in Alzheimer's disease. A precocious onset?. Neuropathology and Applied Neurobiology, 2009, 35, 406-416.	1.8	186
406	Does Alzheimer's disease begin in the brainstem?. Neuropathology and Applied Neurobiology, 2009, 35, 532-554.	1.8	170
407	Frontotemporal lobar degeneration and dementia with Lewy bodies: Clinicopathological issues associated with antemortem diagnosis. Psychogeriatrics, 2009, 9, 91-102.	0.6	3
408	Alzheimer disease with cerebrovascular disease and vascular dementia: clinical features and course compared with Alzheimer disease. Journal of Neurology, Neurosurgery and Psychiatry, 2009, 80, 133-139.	0.9	72
409	Proteomics-derived cerebrospinal fluid markers of autopsy-confirmed Alzheimer's disease. Biomarkers, 2009, 14, 493-501.	0.9	105
410	Proteomics Analysis Reveals Novel Components in the Detergent-Insoluble Subproteome in Alzheimer's Disease. Journal of Proteome Research, 2009, 8, 5069-5079.	1.8	76
411	Neuropathology of nondemented aging: Presumptive evidence for preclinical Alzheimer disease. Neurobiology of Aging, 2009, 30, 1026-1036.	1.5	558
412	CAT53 and HFE alleles in Alzheimer's disease: A putative protective role of the C282Y HFE mutation. Neuroscience Letters, 2009, 457, 129-132.	1.0	15
413	Progressive language impairments: Definitions, diagnoses, and prognoses. Aphasiology, 2009, 23, 302-326.	1.4	12
414	Early risk assessment for Alzheimer's disease. Alzheimer's and Dementia, 2009, 5, 182-196.	0.4	34
415	Neuropathology and Cognitive Impairment in Alzheimer Disease: A Complex but Coherent Relationship. Journal of Neuropathology and Experimental Neurology, 2009, 68, 1-14.	0.9	492
416	Reexamining Alzheimer's Disease: Evidence for a Protective Role for Amyloid-Î <sup>2</sup> Protein Precursor and Amyloid-Î <sup>2</sup> . Journal of Alzheimer's Disease, 2009, 18, 447-452.	1.2	139
417	Abnormal Localization of Leucine-Rich Repeat Kinase 2 to the Endosomal-Lysosomal Compartment in Lewy Body Disease. Journal of Neuropathology and Experimental Neurology, 2009, 68, 994-1005.	0.9	75
418	Increased Matrix Metalloproteinase 9 Activity in Mild Cognitive Impairment. Journal of Neuropathology and Experimental Neurology, 2009, 68, 1309-1318.	0.9	130
419	Thinking Outside the Box: Alzheimer-Type Neuropathology That Does Not Map Directly Onto Current Consensus Recommendations. Journal of Neuropathology and Experimental Neurology, 2010, 69, 449-454.	0.9	33
420	Converging Perturbed Microvasculature and Microglial Clusters Characterize Alzheimer Disease Brain. Current Alzheimer Research, 2010, 7, 625-636.	0.7	26
421	"Hairy Baskets―Associated With Degenerative Purkinje Cell Changes in Essential Tremor. Journal of Neuropathology and Experimental Neurology, 2010, 69, 262-271.	0.9	134

#	Article	IF	CITATIONS
422	William R. Markesbery, MD. Journal of Neuropathology and Experimental Neurology, 2010, 69, 767-768.	0.9	0
423	Distribution and Expression of Picalm in Alzheimer Disease. Journal of Neuropathology and Experimental Neurology, 2010, 69, 1071-1077.	0.9	90
424	Small Vascular and Alzheimer Disease-Related Pathologic Determinants of Dementia in the Oldest-Old. Journal of Neuropathology and Experimental Neurology, 2010, 69, 1247-1255.	0.9	38
425	Transgenic Alzheimer Mice Have a Larger Minimum Alveolar Anesthetic Concentration of Isoflurane than Their Nontransgenic Littermates. Anesthesia and Analgesia, 2010, 110, 438-441.	1.1	18
426	MiR-107 is Reduced in Alzheimer's Disease Brain Neocortex: Validation Study. Journal of Alzheimer's Disease, 2010, 21, 75-79.	1.2	191
427	Neuropathologic Alterations in Mild Cognitive Impairment: A Review. Journal of Alzheimer's Disease, 2010, 19, 221-228.	1.2	202
428	Quantitative Changes in the Mitochondrial Proteome from Subjects with Mild Cognitive Impairment, Early Stage, and Late Stage Alzheimer's Disease. Journal of Alzheimer's Disease, 2010, 19, 325-339.	1.2	36
429	Putative CSF protein biomarker candidates for amnestic mild cognitive impairment. Translational Neuroscience, 2010, 1, 2-8.	0.7	12
430	Alzheimer Disease. Disease-a-Month, 2010, 56, 484-546.	0.4	391
431	Vascular pathology in the aged human brain. Acta Neuropathologica, 2010, 119, 277-290.	3.9	275
432	Prevalence of dementia disorders in the oldest-old: an autopsy study. Acta Neuropathologica, 2010, 119, 421-433.	3.9	215
433	Phosphorylated TDP-43 pathology and hippocampal sclerosis in progressive supranuclear palsy. Acta Neuropathologica, 2010, 120, 55-66.	3.9	97
434	Capillary cerebral amyloid angiopathy identifies a distinct APOE Îμ4-associated subtype of sporadic Alzheimer's disease. Acta Neuropathologica, 2010, 120, 169-183.	3.9	81
435	Biomarker discovery for Alzheimer's disease, frontotemporal lobar degeneration, and Parkinson's disease. Acta Neuropathologica, 2010, 120, 385-399.	3.9	79
436	Apolipoprotein-E forms dimers in human frontal cortex and hippocampus. BMC Neuroscience, 2010, 11, 23.	0.8	25
437	Interpretation of neuropathological lesions: Its limitations in medico-legal experts' reports. Forensic Science International, 2010, 194, e1-e3.	1.3	0
438	Brain pathology in three subjects from the same pedigree with presenilin-1 ( <i>PSEN1</i> ) P264L mutation. Neuropathology and Applied Neurobiology, 2010, 36, 41-54.	1.8	22
439	Association Between Lifetime Cigarette Smoking and Lewy Body Accumulation. Brain Pathology, 2010, 20, 412-418.	2.1	29

#	Article	IF	CITATIONS
440	Omega-3 fatty acids: potential role in the management of early Alzheimer's disease. Clinical Interventions in Aging, 2010, 5, 45.	1.3	143
441	Neocortical Variation of ${\rm Al}^2$ Load in Fully Expressed, Pure Alzheimer's Disease. Journal of Alzheimer's Disease, 2010, 19, 57-68.	1.2	19
442	Diagnostic Tests for Alzheimer's Disease: Rationale, Methodology, and Challenges. International Journal of Alzheimer's Disease, 2010, 2010, 1-6.	1.1	13
443	Biopsy Pathology of Neurodegenerative Disorders in Adults. , 2010, , 551-571.		0
444	Enrichment of cholesterol in microdissected Alzheimer's disease senile plaques as assessed by mass spectrometry. Journal of Lipid Research, 2010, 51, 598-605.	2.0	95
445	Prediction of pathology in primary progressive language and speech disorders. Neurology, 2010, 74, 42-49.	1.5	187
446	Brain Aging in the Oldest-Old. Current Gerontology and Geriatrics Research, 2010, 2010, 1-10.	1.6	37
447	Clinical Nanomedicine: Nanomedical approaches in Alzheimer's disease. European Journal of Nanomedicine, 2010, 3, .	0.6	4
448	Inability of Plasma and Urine F2A-Isoprostane Levels to Differentiate Mild Cognitive Impairment from Alzheimer's Disease. Neurodegenerative Diseases, 2010, 7, 139-142.	0.8	32
449	Where Vascular Meets Neurodegenerative Disease. Stroke, 2010, 41, S144-6.	1.0	120
450	In vivo amyloid imaging in autopsy-confirmed Parkinson disease with dementia. Neurology, 2010, 74, 77-84.	1.5	165
451	Genetic Factors in Alzheimer Disease and Dementia. , 2010, , 681-697.		0
452	Preservation of cortical sortilin protein levels in MCI and Alzheimer's disease. Neuroscience Letters, 2010, 471, 129-133.	1.0	40
453	Cortical M1 receptor concentration increases without a concomitant change in function in Alzheimer's disease. Journal of Chemical Neuroanatomy, 2010, 40, 63-70.	1.0	31
454	Iron-Export Ferroxidase Activity of $\hat{l}^2$ -Amyloid Precursor Protein Is Inhibited by Zinc in Alzheimer's Disease. Cell, 2010, 142, 857-867.	13.5	597
455	Added diagnostic value of CSF biomarkers in differential dementia diagnosis. Neurobiology of Aging, 2010, 31, 1867-1876.	1.5	63
456	Tau-directed drug discovery for Alzheimer's disease and related tauopathies: A focus on tau assembly inhibitors. Experimental Neurology, 2010, 223, 304-310.	2.0	81
457	Imaging correlates of pathology in corticobasal syndrome. Neurology, 2010, 75, 1879-1887.	1.5	203

#	Article	IF	Citations
458	Review Article: Genetics of Alzheimer Disease. Journal of Geriatric Psychiatry and Neurology, 2010, 23, 213-227.	1.2	748
459	Immunohistology of the Nervous System. , 2010, , 820-889.		8
460	Alterations of matrix metalloproteinases in the healthy elderly with increased risk of prodromal Alzheimer's disease. Alzheimer's Research and Therapy, 2010, 2, 20.	3.0	78
461	Neuropathological Alterations in Alzheimer Disease. Cold Spring Harbor Perspectives in Medicine, 2011, 1, a006189-a006189.	2.9	2,365
462	Using Positron Emission Tomography and Florbetapir F 18 to Image Cortical Amyloid in Patients With Mild Cognitive Impairment or Dementia Due to Alzheimer Disease. Archives of Neurology, 2011, 68, 1404.	4.9	310
463	Genetic counseling and testing for Alzheimer disease: Joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors. Genetics in Medicine, 2011, 13, 597-605.	1.1	297
464	Frequency of Alzheimer's disease pathology at autopsy in patients with clinical normal pressure hydrocephalus. Alzheimer's and Dementia, 2011, 7, 509-513.	0.4	121
465	Comparison of Vascular Perturbations in an A $<$ i $>$ î $^2$ -Injected Animal Model and in AD Brain. International Journal of Alzheimer's Disease, 2011, 2011, 1-8.	1.1	28
466	Neuropathology and Amyloid- $\hat{l}^2$ Spectrum in a Bapineuzumab Immunotherapy Recipient. Journal of Alzheimer's Disease, 2011, 24, 315-325.	1.2	26
467	Brainstem: Neglected Locus in Neurodegenerative Diseases. Frontiers in Neurology, 2011, 2, 42.	1.1	69
468	Knowing Me, Knowing You: Can a Knowledge of Risk Factors for Alzheimer's Disease Prove Useful in Understanding the Pathogenesis of Parkinson's Disease?. Journal of Alzheimer's Disease, 2011, 25, 395-415.	1.2	24
469	"End-Stage―Neurofibrillary Tangle Pathology in Preclinical Alzheimer's Disease: Fact or Fiction?. Journal of Alzheimer's Disease, 2011, 25, 445-453.	1.2	42
470	Neuroethical Issues In Early Detection Of Alzheimer'S Disease. , 2011, , .		1
471	Treatment with a $\hat{I}^3$ -Ketoaldehyde Scavenger Prevents Working Memory Deficits in hApoE4 Mice. Journal of Alzheimer's Disease, 2011, 27, 49-59.	1.2	40
472	From Axonal Transport to Mitochondrial Trafficking: What Can We Learn from Manganese-Enhanced MRI Studies in Mouse Models of Alzheimers Disease?. Current Medical Imaging, 2011, 7, 16-27.	0.4	3
473	Alzheimer Disease Pathology in Subjects Without Dementia in 2 Studies of Aging: The Nun Study and the Adult Changes in Thought Study. Journal of Neuropathology and Experimental Neurology, 2011, 70, 832-840.	0.9	65
474	Cognition and Neuropathology in Aging: Multidimensional Perspectives from the Rush Religious Orders Study and Rush Memory and Aging Project. Current Alzheimer Research, 2011, 8, 336-340.	0.7	75
475	Localization of MAP1-LC3 in Vulnerable Neurons and Lewy Bodies in Brains of Patients With Dementia With Lewy Bodies. Journal of Neuropathology and Experimental Neurology, 2011, 70, 264-280.	0.9	55

#	Article	IF	Citations
476	Prediction of Preclinical Alzheimer's Disease: Longitudinal Rates of Change in Cognition. Journal of Alzheimer's Disease, 2011, 25, 707-717.	1.2	39
477	Synaptic changes in frontotemporal lobar degeneration: correlation with MAPT haplotype and APOE genotype. Neuropathology and Applied Neurobiology, 2011, 37, 366-380.	1.8	12
478	Understanding the pathogenesis of Alzheimer's disease: will RNAâ€Seq realize the promise of transcriptomics?. Journal of Neurochemistry, 2011, 116, 937-946.	2.1	65
479	Lipid peroxidation and neurodegenerative disease. Free Radical Biology and Medicine, 2011, 51, 1302-1319.	1.3	308
480	Loss of motor function in preclinical Alzheimer's disease. Expert Review of Neurotherapeutics, 2011, 11, 665-676.	1.4	200
481	Stages of granulovacuolar degeneration: their relation to Alzheimer's disease and chronic stress response. Acta Neuropathologica, 2011, 122, 577-589.	3.9	95
482	Reduced clinical and postmortem measures of cardiac pathology in subjects with advanced Alzheimer's Disease. BMC Geriatrics, 2011, 11, 3.	1.1	18
483	<i>CR1</i> is associated with amyloid plaque burden and ageâ€related cognitive decline. Annals of Neurology, 2011, 69, 560-569.	2.8	148
484	White matter lesions defined by diffusion tensor imaging in older adults. Annals of Neurology, 2011, 70, 465-476.	2.8	104
485	Glucose tolerance status and risk of dementia in the community. Neurology, 2011, 77, 1126-1134.	1.5	374
486	Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important?. Brain, 2011, 134, 1493-1505.	3.7	497
487	Use of Florbetapir-PET for Imaging $\hat{I}^2$ -Amyloid Pathology. JAMA - Journal of the American Medical Association, 2011, 305, 275.	3.8	927
488	Alzheimers Disease: Pathological Mechanisms and Recent Insights. Current Neuropharmacology, 2011, 9, 674-684.	1.4	46
489	Rest tremor in advanced essential tremor: a post-mortem study of nine cases. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 261-265.	0.9	72
490	Midlife and Late-Life Blood Pressure and Dementia in Japanese Elderly. Hypertension, 2011, 58, 22-28.	1.3	214
491	Precuneus amyloid burden is associated with reduced cholinergic activity in Alzheimer disease. Neurology, 2011, 77, 39-47.	1.5	82
492	Clinical features and <i>APOE</i> genotype of pathologically proven early-onset Alzheimer disease. Neurology, 2011, 76, 1720-1725.	1.5	123
493	Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD. Neurology, 2011, 77, 2034-2042.	1.5	281

#	Article	IF	CITATIONS
494	The natural history of cognitive decline in Alzheimer's disease Psychology and Aging, 2012, 27, 1008-1017.	1.4	276
495	Overview and Findings from the Rush Memory and Aging Project. Current Alzheimer Research, 2012, 9, 646-663.	0.7	733
496	The Nun Study: Risk Factors for Pathology and Clinical-Pathologic Correlations. Current Alzheimer Research, 2012, 9, 621-627.	0.7	59
497	Postmortem Pittsburgh Compound B (PiB) Binding Increases with Alzheimer's Disease Progression. Journal of Alzheimer's Disease, 2012, 32, 127-138.	1.2	18
498	Amyloid- $\hat{l}^2$ assessed by florbetapir F 18 PET and 18-month cognitive decline. Neurology, 2012, 79, 1636-1644.	1.5	206
499	Clinical and pathological features of familial frontotemporal dementia caused by C9ORF72 mutation on chromosome 9p. Brain, 2012, 135, 709-722.	3.7	201
500	Biomarkers for the clinical evaluation of the cognitively impaired elderly: amyloid is not enough. Imaging in Medicine, 2012, 4, 343-357.	0.0	12
501	Accuracy of the Clinical Diagnosis of Alzheimer Disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010. Journal of Neuropathology and Experimental Neurology, 2012, 71, 266-273.	0.9	797
502	Pathologic Accumulation of $\hat{l}_{\pm}$ -Synuclein and $\hat{Al^2}$ in Parkinson Disease Patients With Dementia. Archives of Neurology, 2012, 69, 1326.	4.9	173
503	Stable Size Distribution of Amyloid Plaques Over the Course of Alzheimer Disease. Journal of Neuropathology and Experimental Neurology, 2012, 71, 694-701.	0.9	41
504	Hippocampal Drebrin Loss in Mild Cognitive Impairment. Neurodegenerative Diseases, 2012, 10, 216-219.	0.8	75
505	Neuropathological Basis of AlzheimerÂ's Disease and AlzheimerÂ's Disease Diagnosis. Advances in Biological Psychiatry, 2012, , 49-70.	0.2	1
506	Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature. Journal of Neuropathology and Experimental Neurology, 2012, 71, 362-381.	0.9	1,599
507	Saccade Abnormalities in Autopsy-Confirmed Frontotemporal Lobar Degeneration and Alzheimer Disease. Archives of Neurology, 2012, 69, 509.	4.9	97
508	Altered Pharyngeal Muscles in Parkinson Disease. Journal of Neuropathology and Experimental Neurology, 2012, 71, 520-530.	0.9	118
509	Presence of Striatal Amyloid Plaques in Parkinson's Disease Dementia Predicts Concomitant Alzheimer's Disease: Usefulness for Amyloid Imaging. Journal of Parkinson's Disease, 2012, 2, 57-65.	1.5	38
510	Srp20 regulates TrkB preâ€mRNA splicing to generate TrkBâ€6hc transcripts with implications for Alzheimer's disease. Journal of Neurochemistry, 2012, 123, 159-171.	2.1	28
511	Quantitative Analysis of the Detergent-Insoluble Brain Proteome in Frontotemporal Lobar Degeneration Using SILAC Internal Standards. Journal of Proteome Research, 2012, 11, 2721-2738.	1.8	61

#	Article	IF	CITATIONS
512	Neuropathologic substrates of Parkinson disease dementia. Annals of Neurology, 2012, 72, 587-598.	2.8	401
513	Elevated 4-hydroxyhexenal in Alzheimer's disease (AD) progression. Neurobiology of Aging, 2012, 33, 1034-1044.	1.5	76
514	Amyloid beta selectively modulates neuronal TrkB alternative transcript expression with implications for Alzheimer's disease. Neuroscience, 2012, 210, 363-374.	1.1	33
515	Spinal cord lesions in sporadic Parkinson's disease. Acta Neuropathologica, 2012, 124, 643-664.	3.9	130
516	Bid signal pathway components are identified in the temporal cortex with Parkinson disease. Neurology, 2012, 79, 1767-1773.	1.5	15
517	Should Alzheimer's disease be equated with human brain ageing?: A maladaptive interaction between brain evolution and senescence. Ageing Research Reviews, 2012, 11, 104-122.	5.0	18
518	LRP1 expression in cerebral cortex, choroid plexus and meningeal blood vessels: Relationship to cerebral amyloid angiopathy and APOE status. Neuroscience Letters, 2012, 525, 123-128.	1.0	18
519	Smallâ€vessel disease in patients with Parkinson's disease: A clinicopathological study. Movement Disorders, 2012, 27, 1506-1512.	2.2	49
520	Asparaginyl endopeptidase cleaves TDPâ€43 in brain. Proteomics, 2012, 12, 2455-2463.	1.3	52
521	Alzheimer's Disease and the Amyloid $\hat{I}^2$ -Protein. Progress in Molecular Biology and Translational Science, 2012, 107, 101-124.	0.9	106
522	Multiple Findings in Elderly Adults with Confirmed <scp>A</scp> lzheimer's Disease. Journal of the American Geriatrics Society, 2012, 60, 2169-2170.	1.3	0
523	Genetics of Clusterin Isoform Expression and Alzheimer's Disease Risk. PLoS ONE, 2012, 7, e33923.	1.1	60
524	Neuronal LR11 Expression Does Not Differentiate between Clinically-Defined Alzheimer's Disease and Control Brains. PLoS ONE, 2012, 7, e40527.	1.1	10
525	Male Microchimerism in the Human Female Brain. PLoS ONE, 2012, 7, e45592.	1.1	91
526	Striatal Amyloid Plaque Density Predicts Braak Neurofibrillary Stage and Clinicopathological Alzheimer's Disease: Implications for Amyloid Imaging. Journal of Alzheimer's Disease, 2012, 28, 869-876.	1.2	65
527	Ocular Manifestations of Alzheimer's Disease in Animal Models. International Journal of Alzheimer's Disease, 2012, 2012, 1-13.	1.1	45
528	Original article Size frequency distributions of $\hat{l}^2$ -amyloid (A $\hat{l}^2$ ) deposits: a comparative study of four neurodegenerative disorders. Folia Neuropathologica, 2012, 3, 240-249.	0.5	11
529	Contribution of Single Photon Emission Computed Tomography to the Differential Diagnosis of Dementia in a Memory Clinic. Journal of Alzheimer's Disease, 2012, 30, 833-845.	1.2	17

#	Article	IF	CITATIONS
530	Staging and natural history of cerebrovascular pathology in dementia. Neurology, 2012, 78, 1043-1050.	1.5	245
531	TOMM40 in Cerebral Amyloid Angiopathy Related Intracerebral Hemorrhage: Comparative Genetic Analysis with Alzheimer's Disease. Translational Stroke Research, 2012, 3, 102-112.	2.3	23
532	Neuropathological, clinical and molecular pathology in female fragile X premutation carriers with and without FXTAS. Genes, Brain and Behavior, 2012, 11, 577-585.	1.1	117
533	Amyloid Plaques Dissociate Pentameric to Monomeric Câ€Reactive Protein: A Novel Pathomechanism Driving Cortical Inflammation in Alzheimer's Disease?. Brain Pathology, 2012, 22, 337-346.	2.1	70
534	Highâ€molecular weight Aβ oligomers and protofibrils are the predominant Aβ species in the native soluble protein fraction of the AD brain. Journal of Cellular and Molecular Medicine, 2012, 16, 287-295.	1.6	58
535	Neuropathologic analysis of Lewyâ€related αâ€synucleinopathy in olfactory mucosa. Neuropathology, 2013, 33, 47-58.	0.7	42
536	Seizures and Epileptiform Activity in the Early Stages of Alzheimer Disease. JAMA Neurology, 2013, 70, 1158.	4.5	566
537	The <i>APOE</i> Îμ4/Îμ4 Genotype Potentiates Vascular Fibrin(Ogen) Deposition in Amyloid-Laden Vessels in the Brains of Alzheimer's Disease Patients. Journal of Cerebral Blood Flow and Metabolism, 2013, 33, 1251-1258.	2.4	131
538	Genetic Susceptibility for Alzheimer Disease Neuritic Plaque Pathology. JAMA Neurology, 2013, 70, 1150.	4.5	143
539	The unfolded protein response is activated in disease-affected brain regions in progressive supranuclear palsy and Alzheimer's disease. Acta Neuropathologica Communications, 2013, 1, 31.	2.4	148
540	ATP13A2 (PARK9) protein levels are reduced in brain tissue of cases with Lewy bodies. Acta Neuropathologica Communications, 2013, 1, 11.	2.4	61
541	Resting metabolic connectivity in Alzheimer's disease. Clinical and Translational Imaging, 2013, 1, 271-278.	1.1	9
542	Clinical and multimodal biomarker correlates of ADNI neuropathological findings. Acta Neuropathologica Communications, 2013, 1, 65.	2.4	138
543	Age-related appearance of dendritic inclusions in catecholaminergic brainstem neurons. Neurobiology of Aging, 2013, 34, 286-297.	1.5	19
544	Early neuropsychological discriminants for Lewy body disease: an autopsy series. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 1326-1330.	0.9	53
545	A novel melatonin agonist Neu-P11 facilitates memory performance and improves cognitive impairment in a rat model of Alzheimer' disease. Hormones and Behavior, 2013, 64, 1-7.	1.0	92
546	Neuropathologic Basis of Age-Associated Brain Atrophy. JAMA Neurology, 2013, 70, 616.	<b>4.</b> 5	90
547	Screening for predementia AD. Neurology, 2013, 80, 1307-1314.	1.5	96

#	Article	IF	CITATIONS
548	Levels of Soluble Apolipoprotein E/Amyloid- $\hat{l}^2$ (A $\hat{l}^2$ ) Complex Are Reduced and Oligomeric A $\hat{l}^2$ Increased with APOE4 and Alzheimer Disease in a Transgenic Mouse Model and Human Samples*. Journal of Biological Chemistry, 2013, 288, 5914-5926.	1.6	136
549	CD33 Alzheimer's disease locus: altered monocyte function and amyloid biology. Nature Neuroscience, 2013, 16, 848-850.	7.1	485
550	Specific changes of sulfatide levels in individuals with pre linical Alzheimer's disease: an early event in disease pathogenesis. Journal of Neurochemistry, 2013, 127, 733-738.	2.1	84
551	Assessing White Matter Ischemic Damage in Dementia Patients by Measurement of Myelin Proteins. Journal of Cerebral Blood Flow and Metabolism, 2013, 33, 1050-1057.	2.4	64
552	MicroRNA in Alzheimer's disease: an exploratory study in brain, cerebrospinal fluid and plasma. Biomarkers, 2013, 18, 455-466.	0.9	102
553	Molecular Mechanism Aspect of ER Stress in Alzheimer's Disease: Current Approaches and Future Strategies. Current Drug Targets, 2013, 14, 114-122.	1.0	32
554	Cerebral Atherosclerosis Is Associated With Cystic Infarcts and Microinfarcts but Not Alzheimer Pathologic Changes. Stroke, 2013, 44, 2835-2841.	1.0	57
555	Comparison of symptomatic and asymptomatic persons with Alzheimer disease neuropathology. Neurology, 2013, 80, 2121-2129.	1.5	49
556	Clinicopathologic differences among patients with behavioral variant frontotemporal dementia. Neurology, 2013, 80, 561-568.	1.5	84
557	Age and apolipoprotein E ε4 effects on neural correlates of odor memory Behavioral Neuroscience, 2013, 127, 339-349.	0.6	11
558	Examination of the Clinicopathologic Continuum of Alzheimer Disease in the Autopsy Cohort of the National Alzheimer Coordinating Center. Journal of Neuropathology and Experimental Neurology, 2013, 72, 1182-1192.	0.9	89
559	Elevated occipital $\hat{l}^2$ -amyloid deposition is associated with widespread cognitive impairment in logopenic progressive aphasia. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 1357-1364.	0.9	28
560	Dysfunction of the locus coeruleus-norepinephrine system and related circuitry in Parkinson's disease-related dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 774-783.	0.9	199
561	Alpha-Synuclein Pathology and Axonal Degeneration of the Peripheral Motor Nerves Innervating Pharyngeal Muscles in Parkinson Disease. Journal of Neuropathology and Experimental Neurology, 2013, 72, 119-129.	0.9	112
562	Submandibular Gland Biopsy for the Diagnosis of Parkinson Disease. Journal of Neuropathology and Experimental Neurology, 2013, 72, 130-136.	0.9	106
563	Differential Relationships of Reactive Astrocytes and Microglia to Fibrillar Amyloid Deposits in Alzheimer Disease. Journal of Neuropathology and Experimental Neurology, 2013, 72, 462-471.	0.9	163
564	Essential Tremor Followed by Progressive Supranuclear Palsy: Postmortem Reports of 11 Patients. Journal of Neuropathology and Experimental Neurology, 2013, 72, 8-17.	0.9	40
565	Parkinson Disease Affects Peripheral Sensory Nerves in the Pharynx. Journal of Neuropathology and Experimental Neurology, 2013, 72, 614-623.	0.9	123

#	Article	IF	Citations
566	Progranulin Mutations as Risk Factors for Alzheimer Disease. JAMA Neurology, 2013, 70, 774.	4.5	114
567	Endothelin-Converting Enzyme-1 Activity, Endothelin-1 Production, and Free Radical-Dependent Vasoconstriction in Alzheimer's Disease. Journal of Alzheimer's Disease, 2013, 36, 577-587.	1.2	56
568	Increased Apolipoprotein D Dimer Formation in Alzheimer's Disease Hippocampus is Associated with Lipid Conjugated Diene Levels. Journal of Alzheimer's Disease, 2013, 35, 475-486.	1.2	22
569	Neurodegenerative disorders., 0,, 23-71.		О
570	Synapse Stability in the Precuneus Early in the Progression of Alzheimer's Disease. Journal of Alzheimer's Disease, 2013, 35, 599-609.	1,2	50
571	Bapineuzumab Alters A $\hat{l}^2$ Composition: Implications for the Amyloid Cascade Hypothesis and Anti-Amyloid Immunotherapy. PLoS ONE, 2013, 8, e59735.	1.1	30
572	Elevation in Sphingomyelin Synthase Activity Is Associated with Increases in Amyloid-Beta Peptide Generation. PLoS ONE, 2013, 8, e74016.	1.1	17
573	A Systematic Review of Biomarkers for Disease Progression in Alzheimer's Disease. PLoS ONE, 2014, 9, e88854.	1.1	44
574	Obesity and cognitive decline: role of inflammation and vascular changes. Frontiers in Neuroscience, 2014, 8, 375.	1.4	290
575	Positive Florbetapir PET Amyloid Imaging in a Subject with Frequent Cortical Neuritic Plaques and Frontotemporal Lobar Degeneration with TDP43-Positive Inclusions. Journal of Alzheimer's Disease, 2014, 42, 813-821.	1.2	22
576	TAR DNA-binding protein 43 pathology in Alzheimer's disease with psychosis. International Psychogeriatrics, 2014, 26, 987-994.	0.6	13
577	Neuropsychological changes in asymptomatic persons with Alzheimer disease neuropathology. Neurology, 2014, 83, 434-440.	1.5	61
578	24-Hour Rhythms of DNA Methylation and Their Relation with Rhythms of RNA Expression in the Human Dorsolateral Prefrontal Cortex. PLoS Genetics, 2014, 10, e1004792.	1.5	80
579	Factors Determining Disease Duration in Alzheimer's Disease: A Postmortem Study of 103 Cases Using the Kaplan-Meier Estimator and Cox Regression. BioMed Research International, 2014, 2014, 1-7.	0.9	15
580	Pituitary adenylate cyclase–activating polypeptide is reduced in Alzheimer disease. Neurology, 2014, 82, 1724-1728.	1.5	53
581	Neuropathologic Changes Associated With Atrial Fibrillation in a Population-Based Autopsy Cohort. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2014, 69, 609-615.	1.7	40
582	Age at surgical menopause influences cognitive decline and Alzheimer pathology in older women. Neurology, 2014, 82, 222-229.	1.5	292
583	In vivo signatures of nonfluent/agrammatic primary progressive aphasia caused by FTLD pathology. Neurology, 2014, 82, 239-247.	1.5	61

#	Article	IF	Citations
584	Radiation dosimetry of florbetapir F 18. EJNMMI Research, 2014, 4, 4.	1.1	16
585	Practical utility of amyloid and FDG-PET in an academic dementia center. Neurology, 2014, 82, 230-238.	1.5	74
586	Theoretical Impact of Florbetapir ( <sup>18</sup> F) Amyloid Imaging on Diagnosis of Alzheimer Dementia and Detection of Preclinical Cortical Amyloid. Journal of Neuropathology and Experimental Neurology, 2014, 73, 948-953.	0.9	29
587	Clinicopathological Outcomes of Prospectively Followed Normal Elderly Brain Bank Volunteers. Journal of Neuropathology and Experimental Neurology, 2014, 73, 244-252.	0.9	65
588	Alzheimer's diseaseâ€related plaques in nondemented subjects. Alzheimer's and Dementia, 2014, 10, 522-529.	0.4	8
589	ExÂvivo T2 relaxation: associations with age-related neuropathology and cognition. Neurobiology of Aging, 2014, 35, 1549-1561.	1.5	38
590	Concomitant pathologies among a spectrum of parkinsonian disorders. Parkinsonism and Related Disorders, 2014, 20, 525-529.	1.1	107
591	Down-regulation of Mortalin Exacerbates A $\hat{l}^2$ -mediated Mitochondrial Fragmentation and Dysfunction. Journal of Biological Chemistry, 2014, 289, 2195-2204.	1.6	58
592	Abnormal serine phosphorylation of insulin receptor substrate 1 is associated with tau pathology in Alzheimer's disease and tauopathies. Acta Neuropathologica, 2014, 128, 679-689.	3.9	158
593	MicroRNA-339-5p Down-regulates Protein Expression of $\hat{l}^2$ -Site Amyloid Precursor Protein-Cleaving Enzyme 1 (BACE1) in Human Primary Brain Cultures and Is Reduced in Brain Tissue Specimens of Alzheimer Disease Subjects. Journal of Biological Chemistry, 2014, 289, 5184-5198.	1.6	163
594	Deficiency of GDNF Receptor GFR $\hat{i}\pm 1$ in Alzheimer's Neurons Results in Neuronal Death. Journal of Neuroscience, 2014, 34, 13127-13138.	1.7	79
595	New criteria for frontotemporal dementia syndromes: clinical and pathological diagnostic implications. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 865-870.	0.9	195
596	Sleep is related to neuron numbers in the ventrolateral preoptic/intermediate nucleus in older adults with and without Alzheimer's disease. Brain, 2014, 137, 2847-2861.	3.7	136
597	TDP-43 is a key player in the clinical features associated with Alzheimer's disease. Acta Neuropathologica, 2014, 127, 811-824.	3.9	336
598	Assessing THK523 selectivity for tau deposits in Alzheimer's disease and non–Alzheimer's disease tauopathies. Alzheimer's Research and Therapy, 2014, 6, 11.	3.0	68
599	Phosphorylated α-synuclein-immunoreactive retinal neuronal elements in Parkinson's disease subjects. Neuroscience Letters, 2014, 571, 34-38.	1.0	115
600	A comparison of $\hat{Al^2}$ amyloid pathology staging systems and correlation with clinical diagnosis. Acta Neuropathologica, 2014, 128, 543-550.	3.9	26
601	Milk and Dairy Consumption and Risk of Dementia in an Elderly <scp>J</scp> apanese Population: The <scp>H</scp> isayama Study. Journal of the American Geriatrics Society, 2014, 62, 1224-1230.	1.3	92

#	ARTICLE	IF	CITATIONS
602	Axotrophin/MARCH7 acts as an E3 ubiquitin ligase and ubiquitinates tau protein in vitro impairing microtubule binding. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2014, 1842, 1527-1538.	1.8	38
604	Forensic Aspects of Adult and General Neuropathology. , 2014, , 89-262.		0
605	MRI features of Binswanger's disease predict prognosis and associated pathology. Annals of Clinical and Translational Neurology, 2014, 1, 813-821.	1.7	13
606	Anosognosia and Anosodiaphoria in Mild Cognitive Impairment and Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders Extra, 2014, 4, 465-480.	0.6	13
607	Hippocampal Laminar Distribution of Tau Relates to Alzheimer's Disease and Age of Onset. Journal of Alzheimer's Disease, 2014, 43, 315-324.	1.2	12
608	Neuropsychological Markers of Cognitive Decline in Persons With Alzheimer Disease Neuropathology. Journal of Neuropathology and Experimental Neurology, 2015, 74, 1086-1092.	0.9	28
609	Midlife and Lateâ€Life Smoking and Risk of Dementia in the Community: The Hisayama Study. Journal of the American Geriatrics Society, 2015, 63, 2332-2339.	1.3	56
610	<scp>TREM</scp> 2 Protein Expression Changes Correlate with <scp>A</scp>  zheimer's Disease Neurodegenerative Pathologies in Postâ∈Mortem Temporal Cortices. Brain Pathology, 2015, 25, 469-480.	2.1	131
611	Neuropathologic assessment of participants in two multiâ€center longitudinal observational studies: The <scp>A</scp> lzheimer <scp>D</scp> isease <scp>N</scp> euroimaging <scp>I</scp> nitiative ( <scp>ADNI</scp> ) and the <scp>D</scp> ominantly <scp>I</scp> nherited <scp>A</scp> lzheimer <scp>N</scp> etwork ( <scp>DIAN</scp> ). Neuropathology, 2015, 35, 390-400.	0.7	68
612	Alzheimer's disease or <scp>A</scp> lzheimer's syndrome?: a longitudinal computed tomography neuroradiological followâ€up study of 56 cases diagnosed clinically as <scp>A</scp> lzheimer's disease. Psychogeriatrics, 2015, 15, 255-271.	0.6	2
613	Overexpression of Mutant Amyloid-Î <sup>2</sup> Protein Precursor and Presenilin 1 Modulates Enteric Nervous System. Journal of Alzheimer's Disease, 2015, 44, 1263-1278.	1.2	57
614	Feasibility Study: Comparison of Frontal Cortex Needle Core Versus Open Biopsy for Detection of Characteristic Proteinopathies of Neurodegenerative Diseases. Journal of Neuropathology and Experimental Neurology, 2015, 74, 934-942.	0.9	10
615	Pharmacological antagonism of interleukin-8 receptor CXCR2 inhibits inflammatory reactivity and is neuroprotective in an animal model of Alzheimer's disease. Journal of Neuroinflammation, 2015, 12, 144.	3.1	71
616	Clinicopathological characteristics of freezing of gait in autopsyâ€confirmed Parkinson's disease. Movement Disorders, 2015, 30, 1874-1884.	2.2	39
617	Transcriptomics Profiling of Alzheimer's Disease Reveal Neurovascular Defects, Altered Amyloid-β Homeostasis, andÂDeregulated Expression of Long NoncodingÂRNAs. Journal of Alzheimer's Disease, 2015, 48, 647-665.	1.2	157
618	Mass spectrometric identification of citrullination sites and immunohistochemical detection of citrullinated glial fibrillary acidic protein in Alzheimer's disease brains. Journal of Neuroscience Research, 2015, 93, 1664-1674.	1.3	56
619	Neuroimaging in Dementias. , 2015, , 107-118.		0
620	Prion-Protein-interacting Amyloid- $\hat{l}^2$ Oligomers of High Molecular Weight Are Tightly Correlated with Memory Impairment in Multiple Alzheimer Mouse Models. Journal of Biological Chemistry, 2015, 290, 17415-17438.	1.6	104

#	Article	IF	CITATIONS
621	Existing Pittsburgh Compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation. Brain, 2015, 138, 2020-2033.	3.7	319
622	Alpha-Synuclein Pathology in Sensory Nerve Terminals of the Upper Aerodigestive Tract of Parkinson's Disease Patients. Dysphagia, 2015, 30, 404-417.	1.0	36
623	Recognition memory span in autopsy-confirmed Dementia with Lewy Bodies and Alzheimer's Disease. Neuropsychologia, 2015, 75, 548-555.	0.7	8
624	Brain collection, standardized neuropathologic assessment, and comorbidity in Alzheimer's Disease Neuroimaging Initiative 2 participants. Alzheimer's and Dementia, 2015, 11, 815-822.	0.4	46
625	P-glycoprotein expression and amyloid accumulation in human aging and Alzheimer's disease: preliminary observations. Neurobiology of Aging, 2015, 36, 2475-2482.	1.5	95
626	Amyloid βâ€abrogated TrkA ubiquitination in <scp>PC</scp> 12 cells analogous to Alzheimer's disease. Journal of Neurochemistry, 2015, 133, 919-925.	2.1	31
627	The workflow from post-mortem human brain sampling to cell microdissection: a Brain Net Europe study. Journal of Neural Transmission, 2015, 122, 975-991.	1.4	8
628	Parkinson disease and incidental Lewy body disease. Neurology, 2015, 85, 1670-1679.	1.5	88
629	Neuropathological comparisons of amnestic and nonamnestic mild cognitive impairment. BMC Neurology, 2015, 15, 146.	0.8	36
630	Cortical pyroglutamate amyloid- $\hat{l}^2$ levels and cognitive decline in Alzheimer's disease. Neurobiology of Aging, 2015, 36, 12-19.	1.5	29
631	Neurofibrillary Tangle Predominant Dementia: Clinical and Pathological Description in a Case Series. , 2016, 06, .		2
632	Dementia with Lewy Body Disease. , 2016, , .		0
633	Recent Increases in Hippocampal Tau Pathology in the Aging Japanese Population: The Hisayama Study. Journal of Alzheimer's Disease, 2016, 55, 613-624.	1,2	12
634	Amyloid Plaques in Retina for Diagnosis in Alzheimer's Patients: a Meta-Analysis. Frontiers in Aging Neuroscience, 2016, 8, 267.	1.7	28
635	S6 kinase phosphorylated at T229 is involved in tau and actin pathologies in Alzheimer's disease. Neuropathology, 2016, 36, 325-332.	0.7	9
636	Interaction Between Midlife Blood Glucose and APOE Genotype Predicts Later Alzheimer's Disease Pathology. Journal of Alzheimer's Disease, 2016, 53, 1553-1562.	1,2	23
637	Prevalence of Submandibular Gland Synucleinopathy in Parkinson's Disease, Dementia with Lewy Bodies and other Lewy Body Disorders. Journal of Parkinson's Disease, 2016, 6, 153-163.	1.5	58
638	Varying Degrees of Temporoparietal Hypometabolism on FDG-PET Reveal Amyloid-Positive Logopenic Primary Progressive Aphasia is not aÂHomogeneous Clinical Entity. Journal of Alzheimer's Disease, 2016, 55, 1019-1029.	1.2	24

#	Article	IF	CITATIONS
639	FDG-PET in Dementia., 2016,, 73-87.		0
640	Molecular and cellular pathophysiology of preclinical Alzheimer's disease. Behavioural Brain Research, 2016, 311, 54-69.	1.2	99
641	Thal Amyloid Stages Do Not Significantly Impact the Correlation Between Neuropathological Change and Cognition in the Alzheimer Disease Continuum. Journal of Neuropathology and Experimental Neurology, 2016, 75, 516-526.	0.9	67
642	TDP-43 stage, mixed pathologies, and clinical Alzheimer's-type dementia. Brain, 2016, 139, 2983-2993.	3.7	298
643	Incidence and impact of subclinical epileptiform activity in Alzheimer's disease. Annals of Neurology, 2016, 80, 858-870.	2.8	373
644	Caspase-cleaved Tau-D421 is colocalized with the immunophilin FKBP52 in the autophagy-endolysosomal system of Alzheimer's disease neurons. Neurobiology of Aging, 2016, 46, 124-137.	1.5	27
645	Alzheimer Disease and Its Growing Epidemic. Neurologic Clinics, 2016, 34, 941-953.	0.8	114
646	Trends in autopsyâ€verified dementia prevalence over 29Âyears of the Hisayama study. Neuropathology, 2016, 36, 383-387.	0.7	21
647	Relation of genomic variants for Alzheimer disease dementia to common neuropathologies. Neurology, 2016, 87, 489-496.	1.5	68
648	Alpha-synuclein measured in cerebrospinal fluid from patients with Alzheimer's disease, mild cognitive impairment, or healthy controls: a two year follow-up study. BMC Neurology, 2016, 16, 180.	0.8	22
649	ACR–ASNR Practice Parameter for Brain PET/CT Imaging Dementia. Clinical Nuclear Medicine, 2016, 41, 118-125.	0.7	10
650	Gender Differences in Alzheimer Disease: Brain Atrophy, Histopathology Burden, and Cognition. Journal of Neuropathology and Experimental Neurology, 2016, 75, 748-754.	0.9	82
651	Updated TDP-43 in Alzheimer's disease staging scheme. Acta Neuropathologica, 2016, 131, 571-585.	3.9	244
652	Assessing Fluctuating Cognition in Dementia Diagnosis. American Journal of Alzheimer's Disease and Other Dementias, 2016, 31, 137-143.	0.9	24
653	The long-term association between physical activity and risk of dementia in the community: the Hisayama Study. European Journal of Epidemiology, 2016, 31, 267-274.	2.5	67
654	Association of Seafood Consumption, Brain Mercury Level, and <i>APOE <math>\hat{l}\mu 4</math></i> Status With Brain Neuropathology in Older Adults. JAMA - Journal of the American Medical Association, 2016, 315, 489.	3.8	112
655	Plasma sphingolipid changes with autopsyâ€confirmed Lewy body or Alzheimer's pathology. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016, 3, 43-50.	1.2	44
656	Pathological α-synuclein distribution in subjects with coincident Alzheimer's and Lewy body pathology. Acta Neuropathologica, 2016, 131, 393-409.	3.9	123

#	Article	IF	CITATIONS
657	Braak staging, plaque pathology, and APOE status in elderly persons without cognitive impairment. Neurobiology of Aging, 2016, 37, 147-153.	1.5	43
658	Tau aggregation influences cognition and hippocampal atrophy in the absence of beta-amyloid: a clinico-imaging-pathological study of primary age-related tauopathy (PART). Acta Neuropathologica, 2017, 133, 705-715.	3.9	125
659	Clinical and cost implications of amyloid beta detection with amyloid beta positron emission tomography imaging in early Alzheimer's disease – the case of florbetapir. Current Medical Research and Opinion, 2017, 33, 675-685.	0.9	31
660	Typical and atypical pathology in primary progressive aphasia variants. Annals of Neurology, 2017, 81, 430-443.	2.8	288
661	Tooth Loss and Risk of Dementia in the Community: the Hisayama Study. Journal of the American Geriatrics Society, 2017, 65, e95-e100.	1.3	103
662	Late-Onset Alzheimer Disease. Neurologic Clinics, 2017, 35, 283-293.	0.8	42
663	Alzheimer Disease. Mayo Clinic Proceedings, 2017, 92, 978-994.	1.4	57
664	Diurnal and seasonal molecular rhythms in human neocortex and their relation to Alzheimer's disease. Nature Communications, 2017, 8, 14931.	5.8	51
665	Altered microtubule dynamics in neurodegenerative disease: Therapeutic potential of microtubule-stabilizing drugs. Neurobiology of Disease, 2017, 105, 328-335.	2.1	74
666	Statistical considerations for assessing cognition and neuropathology associations in preclinical Alzheimer's disease. Biostatistics and Epidemiology, 2017, 1, 92-104.	0.4	4
667	Rates of hippocampal atrophy and presence of post-mortem TDP-43 in patients with Alzheimer's disease: a longitudinal retrospective study. Lancet Neurology, The, 2017, 16, 917-924.	4.9	159
668	Determining the impact of psychosis on rates of falseâ€positive and falseâ€negative diagnosis in Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2017, 3, 385-392.	1.8	21
669	Four Decades of Research in Alzheimer's Disease (1975–2014): A Bibliometric and Scientometric Analysis. Journal of Alzheimer's Disease, 2017, 59, 763-783.	1.2	33
670	Effect of APOE Genotype on Synaptic Proteins in Earlier Adult Life. Journal of Alzheimer's Disease, 2017, 59, 1123-1137.	1.2	1
671	Alzheimer's Disease Diagnosis: Discrepancy between Clinical, Neuroimaging, and Cerebrospinal Fluid Biomarkers Criteria in an Italian Cohort of Geriatric Outpatients: A Retrospective Cross-sectional Study. Frontiers in Medicine, 2017, 4, 203.	1.2	8
672	Identification of genes associated with dissociation of cognitive performance and neuropathological burden: Multistep analysis of genetic, epigenetic, and transcriptional data. PLoS Medicine, 2017, 14, e1002287.	3.9	88
673	Trajectories of physical function prior to death and brain neuropathology in a community-based cohort: the act study. BMC Geriatrics, 2017, 17, 258.	1.1	4
674	Decreased Expression of Sulfatase 2 in the Brains of Alzheimer's Disease Patients: Implications for Regulation of Neuronal Cell Signaling. Journal of Alzheimer's Disease Reports, 2017, 1, 115-124.	1.2	13

#	Article	IF	CITATIONS
676	Verapamil Inhibits Ser202/Thr205 Phosphorylation of Tau by Blocking TXNIP/ROS/p38 MAPK Pathway. Pharmaceutical Research, 2018, 35, 44.	1.7	50
677	Albuminuria Increases the Risks for Both Alzheimer Disease and Vascular Dementia in Communityâ€Dwelling Japanese Elderly: The Hisayama Study. Journal of the American Heart Association, 2018, 7, .	1.6	40
678	Biopsy Pathology of Neurodegenerative Disorders in Adults. , 2018, , 659-680.		3
679	Susceptibility to neurofibrillary tangles: role of the PTPRD locus and limited pleiotropy with other neuropathologies. Molecular Psychiatry, 2018, 23, 1521-1529.	4.1	58
680	Physical aggression among patients with dementia, neuropathologically confirmed postâ€mortem. International Journal of Geriatric Psychiatry, 2018, 33, e242-e248.	1.3	18
681	Autopsied centenarian case of Alzheimer's disease combined with hippocampal sclerosis, TDPâ€43, and αâ€synuclein pathologies. Neuropathology, 2018, 38, 653-659.	0.7	0
682	Alzheimer's Disease, Visual Search, and Instrumental Activities of Daily Living: A Review and a New Perspective on Attention and Eye Movements. Journal of Alzheimer's Disease, 2018, 66, 901-925.	1.2	11
683	Enhancers active in dopamine neurons are a primary link between genetic variation and neuropsychiatric disease. Nature Neuroscience, 2018, 21, 1482-1492.	7.1	79
684	Seasonal plasticity of cognition and related biological measures in adults with and without Alzheimer disease: Analysis of multiple cohorts. PLoS Medicine, 2018, 15, e1002647.	3.9	42
685	Impaired hepatic amyloid-beta degradation in Alzheimer's disease. PLoS ONE, 2018, 13, e0203659.	1.1	55
686	Cognitive composite score association with Alzheimer's disease plaque and tangle pathology. Alzheimer's Research and Therapy, 2018, 10, 90.	3.0	23
687	Predicting alpha-synuclein pathology by REM sleep behavior disorder diagnosis. Parkinsonism and Related Disorders, 2018, 55, 92-96.	1.1	19
688	Amyloid Accumulation and Cognitive Decline in Clinically Normal Older Individuals: Implications for Aging and Early Alzheimer's Disease. Journal of Alzheimer's Disease, 2018, 64, S633-S646.	1.2	52
689	The Revised National Alzheimer's Coordinating Center's Neuropathology Form—Available Data and New Analyses. Journal of Neuropathology and Experimental Neurology, 2018, 77, 717-726.	0.9	116
690	Diffuse Amyloid-β Plaques, Neurofibrillary Tangles, and the Impact of APOE in Elderly Persons' Brains Lacking Neuritic Amyloid Plaques. Journal of Alzheimer's Disease, 2018, 64, 1307-1324.	1.2	34
691	Neuropathology and cognitive performance in self-reported cognitively healthy centenarians. Acta Neuropathologica Communications, 2018, 6, 64.	2.4	36
692	Modified amyloid variants in pathological subgroups of <i>β</i> â€amyloidosis. Annals of Clinical and Translational Neurology, 2018, 5, 815-831.	1.7	18
693	Melatonin receptor type 1A gene linked to Alzheimer's disease in old age. Sleep, 2018, 41, .	0.6	30

#	Article	IF	Citations
694	Primary Care Mental Health in Older People. , 2019, , .		2
695	Neurocognitive Disorders in Old Age: Alzheimer's Disease, Frontotemporal Dementia, Dementia with Lewy Bodies, and Prion and Infectious Diseases. , 2019, , 251-298.		2
696	Alzheimer's disease-like pathology-triggered oxidative stress, alterations in monoamines levels, and structural damage of locus coeruleus neurons are partially recovered by a mix of proteoglycans of embryonic genesis. Neurochemistry International, 2019, 131, 104531.	1.9	10
697	cindr, the Drosophila Homolog of the CD2AP Alzheimer's Disease Risk Gene, Is Required for Synaptic Transmission and Proteostasis. Cell Reports, 2019, 28, 1799-1813.e5.	2.9	27
698	The neuropathological diagnosis of Alzheimer's disease. Molecular Neurodegeneration, 2019, 14, 32.	4.4	1,497
699	Tauopathy in basal ganglia involvement is exacerbated in a subset of patients with Alzheimer's disease: The Hisayama study. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 415-423.	1.2	15
700	C-terminal and full length TDP-43 specie differ according to FTLD-TDP lesion type but not genetic mutation. Acta Neuropathologica Communications, 2019, 7, 100.	2.4	11
701	Behavioral and Psychiatric Symptoms of Dementia and Rate of Decline in Alzheimer's Disease. Frontiers in Pharmacology, 2019, 10, 1062.	1.6	50
702	Tau-Mediated Disruption of the Spliceosome Triggers Cryptic RNA Splicing and Neurodegeneration in Alzheimer's Disease. Cell Reports, 2019, 29, 301-316.e10.	2.9	118
703	Primary progressive aphasia and the FTD-MND spectrum disorders: clinical, pathological, and neuroimaging correlates. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2019, 20, 146-158.	1.1	23
704	Metabolite Profile of Alzheimer's Disease in the Frontal Cortex as Analyzed by HRMAS 1H NMR. Frontiers in Aging Neuroscience, 2018, 10, 424.	1.7	12
705	Faster cognitive decline in dementia due to Alzheimer disease with clinically undiagnosed Lewy body disease. PLoS ONE, 2019, 14, e0217566.	1.1	31
706	Apathy and Disinhibition Related to Neuropathology in Amnestic Versus Behavioral Dementias. American Journal of Alzheimer's Disease and Other Dementias, 2019, 34, 337-343.	0.9	8
707	The standardization of cerebrospinal fluid markers and neuropathological diagnoses brings to light the frequent complexity of concomitant pathology in Alzheimer's disease: The next challenge for biochemical markers?. Clinical Biochemistry, 2019, 72, 15-23.	0.8	4
708	Transcriptomic analysis of probable asymptomatic and symptomatic alzheimer brains. Brain, Behavior, and Immunity, 2019, 80, 644-656.	2.0	72
709	Interpretable classification of Alzheimer's disease pathologies with a convolutional neural network pipeline. Nature Communications, 2019, 10, 2173.	5.8	116
710	Optimisation and usefulness of quantitative analysis of <sup>18 &lt; /sup&gt;F-florbetapir PET. British Journal of Radiology, 2019, 92, 20181020.</sup>	1.0	20
711	Brain atrophy in primary ageâ€related tauopathy is linked to transactive response DNAâ€binding protein of 43 kDa. Alzheimer's and Dementia, 2019, 15, 799-806.	0.4	14

#	Article	IF	Citations
712	Depression in neurodegenerative diseases: Common mechanisms and current treatment options. Neuroscience and Biobehavioral Reviews, 2019, 102, 56-84.	2.9	159
713	Down-regulated TMED10 in Alzheimer disease induces autophagy via ATG4B activation. Autophagy, 2019, 15, 1495-1505.	4.3	25
714	Association of Neuropathologically Confirmed Frontotemporal Dementia and Alzheimer Disease With Criminal and Socially Inappropriate Behavior in a Swedish Cohort. JAMA Network Open, 2019, 2, e190261.	2.8	25
715	Late Effects., 2019, , 496-554.		O
716	Neuropathological Diagnoses of Demented Hispanic, Black, and Non-Hispanic White Decedents Seen at an Alzheimer's Disease Center. Journal of Alzheimer's Disease, 2019, 68, 145-158.	1.2	56
717	Association of Strawberries and Anthocyanidin Intake with Alzheimer's Dementia Risk. Nutrients, 2019, 11, 3060.	1.7	49
718	Sleep fragmentation, microglial aging, and cognitive impairment in adults with and without Alzheimer's dementia. Science Advances, 2019, 5, eaax7331.	4.7	55
719	Lewy body pathology in Alzheimer's disease: A clinicopathological prospective study. Acta Neurologica Scandinavica, 2019, 139, 76-81.	1.0	32
720	Spectrum of tau pathologies in Huntington's disease. Laboratory Investigation, 2019, 99, 1068-1077.	1.7	23
721	Association analysis of ApoE gene polymorphisms among Egyptian patients with Alzheimer's disease. Gene Reports, 2019, 14, 65-71.	0.4	3
722	Neuropsychological Deficit Profiles, Vascular Risk Factors, and Neuropathological Findings in Hispanic Older Adults with Autopsy-Confirmed Alzheimer's Disease. Journal of Alzheimer's Disease, 2019, 67, 291-302.	1.2	14
723	Coexistence of Multiple Sclerosis and Alzheimer's disease: A review. Multiple Sclerosis and Related Disorders, 2019, 27, 232-238.	0.9	32
724	Is Olfactory Epithelium Biopsy Useful for Confirming Alzheimer's Disease?. Annals of Otology, Rhinology and Laryngology, 2019, 128, 184-192.	0.6	7
725	Decline in Handgrip Strength From Midlife to Late-Life is Associated With Dementia in a Japanese Community: The Hisayama Study. Journal of Epidemiology, 2020, 30, 15-23.	1.1	26
726	Brain and blood metabolome for Alzheimer's dementia: findings from a targeted metabolomics analysis. Neurobiology of Aging, 2020, 86, 123-133.	1.5	83
727	A third of community-dwelling elderly with intermediate and high level of Alzheimer's neuropathologic changes are not demented: A meta-analysis. Ageing Research Reviews, 2020, 58, 101002.	5.0	15
728	Comparative Performance and Neuropathologic Validation of the AD8 Dementia Screening Instrument. Alzheimer Disease and Associated Disorders, 2020, 34, 112-117.	0.6	9
729	Blood-based protein mediators of senility with replications across biofluids and cohorts. Brain Communications, 2020, 2, fcz036.	1.5	11

#	ARTICLE	IF	CITATIONS
730	Functional genomic analyses uncover APOE-mediated regulationÂofÂbrain and cerebrospinal fluid beta-amyloid levels in Parkinson disease. Acta Neuropathologica Communications, 2020, 8, 196.	2.4	8
731	Late-onset vs nonmendelian early-onset Alzheimer disease. Neurology: Genetics, 2020, 6, e512.	0.9	82
732	RT-QuIC detection of tauopathies using full-length tau substrates. Prion, 2020, 14, 249-256.	0.9	16
733	Accuracy of Biomarker Testing for Neuropathologically Defined Alzheimer Disease in Older Adults With Dementia. Annals of Internal Medicine, 2020, 172, 669-677.	2.0	25
734	Targeting isoaspartate-modified Aβ rescues behavioral deficits in transgenic mice with Alzheimer's disease-like pathology. Alzheimer's Research and Therapy, 2020, 12, 149.	3.0	10
735	Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders. JAMA - Journal of the American Medical Association, 2020, 324, 772.	3.8	640
736	Hippocampal sclerosis, TDPâ€43, and the duration of the symptoms of dementia of AD patients. Annals of Clinical and Translational Neurology, 2020, 7, 1546-1556.	1.7	15
737	Molecular abnormalities in autopsied brain tissue from the inferior horn of the lateral ventricles of nonagenarians and Alzheimer disease patients. BMC Neurology, 2020, 20, 317.	0.8	15
738	Prevalence and clinical associations of tau in Lewy body dementias: A systematic review and meta-analysis. Parkinsonism and Related Disorders, 2020, 80, 184-193.	1.1	21
739	Significance of Blood and Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: Sensitivity, Specificity and Potential for Clinical Use. Journal of Personalized Medicine, 2020, 10, 116.	1.1	26
740	Post-mortem analyses of PiB and flutemetamol in diffuse and cored amyloid-l̂² plaques in Alzheimer's disease. Acta Neuropathologica, 2020, 140, 463-476.	3.9	34
741	Peripheral serum metabolomic profiles inform central cognitive impairment. Scientific Reports, 2020, 10, 14059.	1.6	25
742	Women's higher brain metabolic rate compensates for early Alzheimer's pathology. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12121.	1.2	8
743	Association of serial position scores on memory tests and hippocampal-related neuropathologic outcomes. Neurology, 2020, 95, e3303-e3312.	1.5	9
744	Protein contributions to brain atrophy acceleration in Alzheimer's disease and primary age-related tauopathy. Brain, 2020, 143, 3463-3476.	3.7	45
745	Cognitive decline profiles differ in Parkinson disease dementia and dementia with Lewy bodies. Neurology, 2020, 94, e2076-e2087.	1.5	42
746	The lipid phosphatase Synaptojanin 1 undergoes a significant alteration in expression and solubility and is associated with brain lesions in Alzheimer $\hat{a} \in \mathbb{N}$ s disease. Acta Neuropathologica Communications, 2020, 8, 79.	2.4	15
747	Relationships between amyloid levels, glucose metabolism, morphologic changes in the brain and clinical status of patients with Alzheimer's disease. Annals of Nuclear Medicine, 2020, 34, 337-348.	1.2	13

#	Article	IF	CITATIONS
748	Association between clinical symptoms and postâ€mortem neuropathology in dementia with Lewy bodies. Geriatrics and Gerontology International, 2020, 20, 261-262.	0.7	3
749	Prevalence and Clinical Phenotype of Quadruple Misfolded Proteins in Older Adults. JAMA Neurology, 2020, 77, 1299.	4.5	109
750	Lifetime cumulative incidence of dementia in a community-dwelling elderly population in Japan. Neurology, 2020, 95, e508-e518.	1.5	10
751	The Utility of the National Alzheimer's Coordinating Center's Database for the Rapid Assessment of Evolving Neuropathologic Conditions. Alzheimer Disease and Associated Disorders, 2020, 34, 105-111.	0.6	19
752	Cell death and survival pathways in Alzheimer's disease: an integrative hypothesis testing approach utilizing -omic data sets. Neurobiology of Aging, 2020, 95, 15-25.	1.5	23
<b>7</b> 53	Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia. Nature Medicine, 2020, 26, 379-386.	15.2	643
754	Validation of machine learning models to detect amyloid pathologies across institutions. Acta Neuropathologica Communications, 2020, 8, 59.	2.4	20
755	Severe hyposmia distinguishes neuropathologically confirmed dementia with Lewy bodies from Alzheimer's disease dementia. PLoS ONE, 2020, 15, e0231720.	1.1	27
756	Association between transactive response DNA-binding protein ofÂ43 kDa type and cognitive resilience to Alzheimer's disease: aÂcase-control study. Neurobiology of Aging, 2020, 92, 92-97.	1.5	13
757	Principal-Component Analysis–Based Measures of PET Data Closely Reflect Neuropathologic Staging Schemes. Journal of Nuclear Medicine, 2021, 62, 855-860.	2.8	6
758	Is Levodopa Response a Valid Indicator of Parkinson's Disease?. Movement Disorders, 2021, 36, 948-954.	2.2	26
759	Dietary carotenoids related to risk of incident Alzheimer dementia (AD) and brain AD neuropathology: a community-based cohort of older adults. American Journal of Clinical Nutrition, 2021, 113, 200-208.	2.2	46
760	Utility of MRI in the identification of hippocampal sclerosis of aging. Alzheimer's and Dementia, 2021, 17, 847-855.	0.4	15
762	Decrease of neuronal FKBP4/FKBP52 modulates perinuclear lysosomal positioning and MAPT/Tau behavior during MAPT/Tau-induced proteotoxic stress. Autophagy, 2021, 17, 3491-3510.	4.3	12
764	Amyloid burden quantification depends on PET and MR image processing methodology. PLoS ONE, 2021, 16, e0248122.	1.1	5
765	Age-at-Onset and <i>APOE</i> -Related Heterogeneity in Pathologically Confirmed Sporadic Alzheimer Disease. Neurology, 2021, 96, e2272-e2283.	1.5	15
766	Identification of retinoblastoma binding protein 7 (Rbbp7) as a mediator against tau acetylation and subsequent neuronal loss in Alzheimer's disease and related tauopathies. Acta Neuropathologica, 2021, 142, 279-294.	3.9	13
768	Abnormal brain cholesterol homeostasis in Alzheimer's diseaseâ€"a targeted metabolomic and transcriptomic study. Npj Aging and Mechanisms of Disease, 2021, 7, 11.	4.5	59

#	ARTICLE	IF	Citations
769	Cognitive Activity and Onset Age of Incident Alzheimer Disease Dementia. Neurology, 2021, 97, e922-e929.	1.5	18
770	The complexity of Alzheimer's disease: an evolving puzzle. Physiological Reviews, 2021, 101, 1047-1081.	13.1	110
772	Data-Driven vs Consensus Diagnosis of MCI. Neurology, 2021, 97, e1288-e1299.	1.5	12
773	The association of epigenetic clocks in brain tissue with brain pathologies and common aging phenotypes. Neurobiology of Disease, 2021, 157, 105428.	2.1	36
774	Epigenomic features related to microglia are associated with attenuated effect of <i>APOE</i> $\hat{l}\mu 4$ on Alzheimer's disease risk in humans. Alzheimer's and Dementia, 2022, 18, 688-699.	0.4	9
775	Association of clusterin with the BRI2-derived amyloid molecules ABri and ADan. Neurobiology of Disease, 2021, 158, 105452.	2.1	5
776	New Neuropathological Criteria for Alzheimer Disease. Archives of Neurology, 1998, 55, 1174-1176.	4.9	78
777	Protein-Based Neuropathology and Molecular Classification of Human Neurodegenerative Diseases. Focus on Structural Biology, 2009, , 251-272.	0.1	5
778	Functional Imaging and Psychopathological Consequences of Inflammation in Alzheimer's Dementia. , 2005, , 75-83.		2
779	Biological markers for the diagnosis of Alzheimer's disease. Journal of Neural Transmission Supplementum, 1998, 53, 185-197.	0.5	7
780	Immunohistochemistry Applications in Pathology. , 2008, , 493-515.		1
781	Types of Age-Related Brain Lesions and Relationship to Neuropathologic Diagnostic Systems of Alzheimer's Disease., 2001,, 65-76.		2
783	Laminar specific loss of isocortical presenilin $1$ immunoreactivity in Alzheimer's disease. Correlations with the amyloid load and the density of tau-positive neurofibrillary tangles. Neuropathology and Applied Neurobiology, 2000, 26, 117-123.	1.8	10
787	Neurodegeneration in Normal Brain Aging and Disease. Science of Aging Knowledge Environment: SAGE KE, 2004, 2004, pe26-pe26.	0.9	106
788	The Development of Amyloid beta Protein Deposits in the Aged Brain. Science of Aging Knowledge Environment: SAGE KE, 2006, 2006, re1-re1.	0.9	174
789	Forensic Aspects of Adult General Neuropathology. , 2008, , 79-246.		1
790	Frequency of Biologically Defined Alzheimer Disease in Relation to Age, Sex, <i>APOE</i> $\hat{l}\mu$ 4, and Cognitive Impairment. Neurology, 2021, 96, e975-e985.	1.5	42
791	Clinical and quantitative pathologic correlates of dementia with Lewy bodies. Neurology, 1999, 53, 1284-1284.	1.5	167

#	ARTICLE	IF	CITATIONS
792	The search for disease modification in moderate to severe Alzheimer disease. Neurology, 2005, 65, .	1.5	5
793	Intermediate Phenotypes Identify Divergent Pathways to Alzheimer's Disease. PLoS ONE, 2010, 5, e11244.	1.1	41
794	The Response of Cerebral Cortex to Haemorrhagic Damage: Experimental Evidence from a Penetrating Injury Model. PLoS ONE, 2013, 8, e59740.	1.1	33
795	Animal models of Alzheimer disease: historical pitfalls and a path forward. ALTEX: Alternatives To Animal Experimentation, 2014, 31, 279-302.	0.9	95
796	Selectively Reduced Expression of Synaptic Plasticity-Related Genes in Amyloid Precursor Protein + Presenilin-1 Transgenic Mice. Journal of Neuroscience, 2003, 23, 5219-5226.	1.7	223
797	Assessment of Persistent, Bioaccumulative and Toxic Organic Environmental Pollutants in Liver and Adipose Tissue of Alzheimer's Disease Patients and Age-matched Controls. Current Alzheimer Research, 2019, 16, 1039-1049.	0.7	9
798	A Pragmatic Approach to the Postmortem Neuropathological Diagnosis of Dementia. Academic Forensic Pathology, 2012, 2, 2-9.	0.3	2
799	Is there a neuropathology difference between mild cognitive impairment and dementia?. Dialogues in Clinical Neuroscience, 2009, 11, 171-179.	1.8	38
800	Gray Matter Atrophy Associated with Extrapyramidal Signs in the Lewy Body Variant of Alzheimer's Disease. Journal of Alzheimer's Disease, 2012, 32, 1043-1049.	1.2	2
801	Comorbidity in Dementia. Archives of Pathology and Laboratory Medicine, 2004, 128, 32-38.	1.2	86
802	Dementias. , 2003, , 199-242.		0
804	Water quality and cholesterol-induced pathology: differential effects of the M-1 muscarinic receptor agonist AF267B on accumulation of Alzheimer-like amyloid $\hat{l}^2$ in rabbit brain DL Sparks, J Lochhead, A Fisher, T Martin. , 2005, , 219-226.		0
805	Neuroimaging in Alzheimer Disease. , 2006, , 142-159.		3
806	Neurodegenerative disorders. , 2007, , 395-412.		0
807	Molecular Imaging in Biology and Pharmacology. , 2008, , 457-XLV.		0
808	Clinical Evaluation and Treatment of Cognitive Dysfunction and Dementia., 2009,, 103-127.		0
809	ALZHEIMER'S DISEASE AND DEMENTIAS., 2009,, 641-649.		0
810	Introduction: Still More Questions than Answers. , 2009, , 3-10.		0

#	Article	IF	CITATIONS
811	10 Neuroimaging in Alzheimer Disease. , 2011, , 167-182.		0
820	Different rates of cognitive decline in autosomal dominant and lateâ€onset Alzheimer disease. Alzheimer's and Dementia, 2022, 18, 1754-1764.	0.4	4
821	One-Carbon Metabolism in Alzheimer's Disease and Parkinson's Disease Brain Tissue. Nutrients, 2022, 14, 599.	1.7	15
822	Targeted Metabolomic Analysis in Alzheimer's Disease Plasma and Brain Tissue in Non-Hispanic Whites. Journal of Alzheimer's Disease, 2022, 86, 1875-1895.	1.2	17
823	The changing landscape of neuroimaging in frontotemporal lobar degeneration: from group-level observations to single-subject data interpretation. Expert Review of Neurotherapeutics, 2022, 22, 179-207.	1.4	8
824	Clinical Trajectories at the End of Life in Autopsy-Confirmed Dementia Patients With Alzheimer Disease and Lewy Bodies Pathologies. Neurology, 2022, 98, .	1.5	9
825	Cerebral Atrophy. , 0, , 222-248.		0
826	<i>APOE</i> $\hat{l}\mu$ 4 and Alzheimer's Disease Diagnosis Associated Differences in L-Carnitine, GBB, TMAO and Acylcarnitines in Blood and Brain. SSRN Electronic Journal, 0, , .	0.4	0
827	Proteome-Wide Discovery of Cortical Proteins That May Provide Motor Resilience to Offset the Negative Effects of Pathologies in Older Adults. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2023, 78, 494-503.	1.7	4
828	Immunohistochemical Demonstration of the pGlu79 α-Synuclein Fragment in Alzheimer's Disease and Its Tg2576 Mouse Model. Biomolecules, 2022, 12, 1006.	1.8	2
829	Perception of Fragmented Letters by Patients With Pathologically Confirmed Dementia With Lewy Bodies or Alzheimer Disease. Neurology, 2022, 99, .	1.5	2
831	APOE ε4 and Alzheimer's disease diagnosis associated differences in L-carnitine, GBB, TMAO, and acylcarnitines in blood and brain. Current Research in Translational Medicine, 2023, 71, 103362.	1.2	3
833	Longitudinal change in serial position scores in older adults with entorhinal and hippocampal neuropathologies. Journal of the International Neuropsychological Society, 2023, 29, 561-571.	1.2	3
834	Mid―and laterâ€ife risk factors for predicting neuropathological brain changes associated with Alzheimer's and vascular dementia: The Honolulu Asia Aging Study and the Age, Gene/Environment Susceptibilityâ€Reykjavik Study. Alzheimer's and Dementia, 2023, 19, 1705-1713.	0.4	2
835	Brain copper may protect from cognitive decline and Alzheimer's disease pathology: a community-based study. Molecular Psychiatry, 2022, 27, 4307-4313.	4.1	11
836	Gene Expression Analysis of Laser-Captured Purkinje Cells in the Essential Tremor Cerebellum. Cerebellum, 2023, 22, 1166-1181.	1.4	2
839	The Role of Copper Homeostasis in Brain Disease. International Journal of Molecular Sciences, 2022, 23, 13850.	1.8	30
841	Somatic copy number variant load in neurons of healthy controls and Alzheimer's disease patients. Acta Neuropathologica Communications, 2022, 10, .	2.4	3

#	Article	IF	CITATIONS
842	Jacobâ€induced transcriptional inactivation of <scp>CREB</scp> promotes Aβâ€induced synapse loss in Alzheimer's disease. EMBO Journal, 2023, 42, .	3.5	9
843	Marital Status of Never Married with Rey Auditory Verbal Learning Test Cognition Performance Is Associated with Mild Cognitive Impairment. Applied Sciences (Switzerland), 2023, 13, 1656.	1.3	2
844	SUFI: an automated approach to spectral unmixing of fluorescent multiplex images captured in mouse and post-mortem human brain tissues. BMC Neuroscience, 2023, 24, .	0.8	2
845	Association of Mediterranean-DASH Intervention for Neurodegenerative Delay and Mediterranean Diets With Alzheimer Disease Pathology. Neurology, 2023, 100, .	1.5	24
847	Microglia directly associate with pericytes in the central nervous system. Glia, 2023, 71, 1847-1869.	2.5	7
849	Ultra-high field imaging, plasma markers and autopsy data uncover a specific rostral locus coeruleus vulnerability to hyperphosphorylated tau. Molecular Psychiatry, 2023, 28, 2412-2422.	4.1	4